aan Oe
ea es
1 |
‘.
= sf m™ PUBLIC HEACTH | IBRARY
% 4 No. 91-13
oe U5
ce mH AUG ¥5 1993
‘
1

 

ethene colenenem,

BIB ILIOGIRAIPHIIBS
JUN MU IDICCIONTE,

PUBL

 

  
 
 
  
     
    

Diagnosis and
Treatment of
Early
Melanoma

 

 

 

 

 

 

 

   

, National Library
[ of Medicine

January 1983
through
November 1991

 

 

 

 

 

 

 

447 Citations

 

 

 

 

 

 

 

 

 

 

 

 

- U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
Public Health Service ¢ National Institutes of Health

DOC. X
''PUBLIC HEALTH LIBRARY

j aeacicey
| LIBRARY

UNIVERSITY OF

\. CALIFORNIA

 
''CBM 91-13

Diagnosis and Treatment of Early Melanoma

January 1983 through November 1991

447 Citations

Prepared by
Karen Patrias, M.L.S., National Library of Medicine

Alan N. Moshell, M.D., National Institute of Arthritis and Musculoskeletal and Skin Diseases

U.S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES

Public Health Service

National Institutes of Health

National Library of Medicine
Reference Section

8600 Rockville Pike
Bethesda, Maryland 20894
''SERIES NOTE

Current Bibliographies in Medicine (CBM) is a continuation in part of the National Library of Medicine’ s
Literature Search Series, which ceased in 1987 with No. 87-15. In 1989 it also subsumed the Specialized
Bibliography Series. Each bibliography in the new series covers a distinct subject area of biomedicine
and is intended to fulfill a current awareness function. Citations are usually derived from searching a
variety of online databases. NLM databases utilized include MEDLINE®, AVLINE®, BIOETHICSLINE®,
CANCERLIT®, CATLINE®, HEALTH, POPLINE™ and TOXLINE®. The only criterion for the inclusion
of a particular published work is its relevance to the topic being presented; the format, ownership, or
location of the material is not considered.

Comments and suggestions on this series may be addressed to:

Karen Patrias, Editor

Current Bibliographies in Medicine
Reference Section

National Library of Medicine
Bethesda, MD 20894
301/496-6097

Ordering Information:

Current Bibliographies in Medicine is sold by the Superintendent of Documents, U.S. Government
Printing Office, Washington, D.C. 20402. To order the entire CBM series for the calendar year 1991
(20 bibliographies), send $52.00 ($65.00 foreign) to the Superintendent of Documents citing GPO List
ID: CBM91. For your convenience an order blank is given inside the back cover. Orders for individual
bibliographies in the series ($3.00, $3.75 foreign) should be sent to the Superintendent of Documents
citing the title, CBM number, and the GPO List ID given above.

Use of funds for printing this periodical has been approved by the Director
of the Office of Management and Budget through September 30, 1992.

ii
''DIAGNOSIS AND TREATMENT OF EARLY MELANOMA

The incidence of malignant melanoma is rising rapidly. This malignancy is often fatal if not diagnosed
and treated promptly. However, it has become clear that the specific clinical and histologic criteria for
such early diagnosis is not completely agreed upon. Similarly, recent studies have indicated that the
treatment for early melanoma may not need to be as aggressive as previously recommended without
compromising cure rates.

There has been great public awareness of malignant melanoma and, in some cases, unnecessary fear of
both the development of the disease and its treatment. At the same time, intervention has the potential
of providing greatly improved cure rates in the treatment of this disease. However, for this potential to
be recognized, it must be possible to identify melanoma at its earliest stages, clinically and histologically,
and to educate the population to the necessity for early diagnosis and treatment.

This bibliography was prepared in support of the National Institutes of Health Consensus Development
Conference titled Diagnosis and Treatment of Early Melanoma held in Bethesda, Maryland on January
27-29, 1992. It consists of citations to English language journal articles, conference papers, and books
and book chapters written from 1983 to the present. All aspects of the diagnosis and treatment of early
melanoma have been covered, as well as articles on epidemiology, etiology, prevention, public health, and
public education. Dysplastic nevi, both as part of the dysplastic nevus syndrome and as sporadic
occurrences, have also been included. Only items dealing with human studies are present, although
occasional articles include both humans and animals. For the most part, citations have been limited to
full scale, original articles or reviews rather than editorials, letters, or other similar short communications.
Preference has also been given to articles appearing in refereed journals. Arrangement of the bibliography
is by the five following subject categories, which parallel the organization of the scientific presentations
at the Consensus Conference: clinical characteristics of early melanoma (excluding dysplastic nevi);
pathology of early melanoma; dysplastic nevus syndrome and dysplastic nevi; evaluation of the patient
and family following the diagnosis of early melanoma; and epidemiology, prevention, and treatment of
early melanoma. Individual citations are listed only once in the most appropriate category.

ili
''SEARCH STRATEGY

A variety of online databases are usually searched in preparing bibliographies in the CBM series. To
assist you in updating or otherwise manipulating the material in this search, the strategy used for the
NLM’s MEDLINE database is given below. Please note that the search strategies presented here differ
from individual demand searches in that they are generally broadly formulated and irrelevant citations
edited out prior to printing.

SS 1=*MELANOMA OR ALL MELANOMA: (TF)

SS 2=1 AND NOT MELANOMA, EXPERIMENTAL

SS 3 = *DYSPLASTIC NEVUS SYNDROME

SS 4=*NEVUS OR *NEVUS, PIGMENTED OR *MELANOMA
SS 5=(TF) NEVI OR NEVUS OR ALL NAEV:

SS6=4 OR 5

SS 7=6 AND ALL DYSPLAS: (TW) OR 6 AND ALL MELANOCYT: (TW)
SS 8=(TF) ALL DYSPLAS: AND ALL MELANOCYT:

SS 9 = (TF) ALL MOLE# AND ATYPICAL OR FAMMM
SS10=2 OR 3 OR 7 OR 8 OR 9

SS11 = 10 AND NOT FOR (LA)

SS12 = 11 AND HUMAN

GRATEFUL MED®

To make online searching easier and more efficient, the Library offers GRATEFUL MED,
microcomputer-based software that provides a user-friendly interface to most NLM databases. This
software was specifically developed for health professionals and features multiple choice menus and "fill
in the blank" screens for easy search preparation. GRATEFUL MED runs on an IBM PC (or IBM-
compatible) with DOS 2.0 or a Macintosh, and requires a Hayes (or Hayes-compatible) modem. It may
be purchased from the National Technical Information Service in Springfield, Virginia, for $29.95 (plus
$3.00 per order for shipping). For your convenience, an order blank has been enclosed at the back of this
bibliography.

iv
''SAMPLE CITATIONS

Citations in this bibliographic series are formatted according to the rules established for Index Medicus®*.
Sample journal and monograph citations appear below. Note also that a colon (:) may appear within an
author’s name or article title. The NLM computer system automatically inserts this symbol in the place
of a diacritical mark.

Journal Article:
Authors Article Title

x
Dawber RP, Colver GB. The spectrum of malignant melanoma of the nail apparatus.
Semin Dermatol 1991 Mar;10(1):82-7.
a we ff , oN

Abbreviated Journal Date Volume Issue Pages

Title
Monograph:
Authors/Editors Title
so \

Balch CM, Milton GW, editors. Cutaneous melanoma. Clinical management and treatment
results worldwide. Philadelphia: J. B. Lippincott Company; 1985. 538 p.
| | / |
Place of Publisher Date Total No.
Publication of Pages

 

*For details of the formats used for references, see the following publication:

Patrias, Karen. National Library of Medicine recommended formats for bibliographic citation.
Bethesda (MD): The Library; 1991 Apr. Available from: NTIS, Springfield, VA; PB91-182030.
''vi
''TABLE OF CONTENTS

Clinical Characteristics (excluding Dysplastic
Nevus Syndrome)

Pathology
Dysplastic Nevus Syndrome and Dysplastic Nevi

Evaluation of Patient and Family
Following Diagnosis

Epidemiology, Prevention, and Treatment

Vil

page
''Vili
''Clinical Characteristics (excluding
Dysplastic Nevus Syndrome)

Becker JK, Goldberg LH, Tschen JA. Differential
diagnosis of malignant melanoma. Am Fam
Physician 1989 May;39(5):203-14.

Cascinelli N, Ferrario M, Tonelli T, Leo E. A possible
new tool for clinical diagnosis of melanoma: the
computer. J Am Acad Dermatol 1987 Feb;16(2 Pt
1):361-7.

Cassileth BR, Clark WH Jr, Lusk EJ, Frederick BE,
Thompson CJ, Walsh WP. How well do
physicians recognize melanoma and other problem
lesions? J Am Acad Dermatol 1986 Apr;14(4):
555-60.

Cassileth BR, Lusk EJ, Guerry D 4th, Clark WH Jr,
Matozzo I, Frederick BE. "Catalyst" symptoms in
malignant melanoma. J Gen Intern Med 1987 Jan-
Feb;2(1):1-4.

Cassileth BR, Temoshok L, Frederick BE, Walsh WP,
Hurwitz S, Guerry D, Clark WH Jr, DiClemente RJ,
Sweet DM, Blois MS, et al. Patient and physician
delay in melanoma diagnosis. J Am Acad Dermatol
1988 Mar;18(3):591-8.

Chanda JJ. The clinical recognition and prognostic
factors of primary cutaneous malignant melanoma.
Med Clin North Am 1986 Jan;70(1):39-55.

Dawber RP, Colver GB. The spectrum of malignant
melanoma of the nail apparatus. Semin Dermatol
1991 Mar;10(1):82-7.

Dhawan AP. An expert system for the early detection

of melanoma using knowledge-based image analysis.

Anal Quant Cytol Histol 1988 Dec;10(6):405-16.

Dhawan AP. Early detection of cutaneous malignant
melanoma by three-dimensional nevoscopy.
Comput Methods Programs Biomed 1985 Oct;21(1):
59-68.

Evans JF, Miller OF. Malignant melanoma and its
precursors. The growing need for early
identification. Postgrad Med 1986 Feb 1;79(2):
215-22.

Funk W, Schmoeckel C, H:olzel D, Braun-Falco O.
Prognostic classification of malignant melanoma by
clinical criteria. Br J Dermatol 1984 Aug;111(2):
129-38.

Grin CM, Kopf AW, Welkovich B, Bart RS, Levenstein
MJ. Accuracy in the clinical diagnosis of
malignant melanoma [published erratum appears in
Arch Dermatol 1990 Nov;126(11):1461] [see

comments]. Arch Dermatol 1990 Jun;126(6):763-6.
Comment in: Arch Dermatol 1990 Dec;126(12):
1651, 1654.

Hoss DM, Grant-Kels JM. Significant melanocytic
lesions in infancy, childhood, and adolescence.
Dermatol Clin 1986 Jan;4(1):29-44.

Keefe M, Dick DC, Wakeel RA. A study of the value
of the seven-point checklist in distinguishing benign
pigmented lesions from melanoma [see comments].
Clin Exp Dermatol 1990 May;15(3):167-71.
Comment in: Clin Exp Dermatol 1991 Mar;16(2):
151-3.

Kelly JW, Crutcher WA, Sagebiel RW. Clinical
diagnosis of dysplastic melanocytic nevi. A
clinicopathologic correlation. J Am Acad Dermatol
1986 Jun;14(6):1044-52.

Kraus W, Schramm P, Hoede N. First experiences
with a high-resolution ultrasonic scanner in the
diagnosis of malignant melanomas. Arch Dermatol
Res 1983;275(4):235-8.

Landow RK. Differential diagnosis and treatment of
pigmented skin lesions. Compr Ther 1988 Apr;
14(4):25-32.

Larsen TE, Mogensen SB, Holme I. The evaluation of
possible melanoma risk groups of patients in a
series of pigmented naevi. Clinical and histological
intercorrelations. Acta Derm Venereol (Stockh)
1988;68(2):134-9.

Lennon GM, Griffin M, O’Briain DS, Cassidy M,
Caldwell M, Young M, Tanner WA, Keane FB.
Malignant melanoma lately diagnosed. Ir Med J
1989 Sep;82(3):109-11.

Lookingbill DP. Yield from a complete skin
examination. Findings in 1157 new dermatology
patients. J Am Acad Dermatol 1988 Jan;18(1 Pt
1):31-7,

MacKie RM. Risk factors, diagnosis, and detection of
melanoma. Curr Opin Oncol 1991 Apr;3(2):360-3.

Masri GD, Clark WH Jr, Guerry D 4th, Halpern A,
Thompson CJ, Elder DE. Screening and
surveillance of patients at high risk for malignant
melanoma result in detection of earlier disease.

J Am Acad Dermatol 1990 Jun;22(6 Pt 1):1042-8.

Milton GW, Balch CM, Shaw HM. Cutaneous
melanoma: clinical characteristics. In: Balch CM,
Milton GW, editors. Cutaneous melanoma. Clinical
management and treatment results worldwide.
Philadelphia: J.B. Lippincott Company; 1985.

p. 13-28.
''2

Pritchard GA, Hughes LE. Clinical assessment of
melanoma thickness. Eur J Surg Oncol 1989 Jun;
15(3):232-5.

Rampen FH, R:umke P. Referral pattern and accuracy
of clinical diagnosis of cutaneous melanoma. Acta
Derm Venereol (Stockh) 1988;68(1):61~4.

Rampen FH, R:umke P, Hart AA. Patients’ and
doctors’ delay in the diagnosis and treatment of
cutaneous melanoma. Eur J Surg Oncol 1989 Apr;
15(2):143-8.

Redman JC. All melanomas start sometime: what to do
before and after. Postgrad Med 1983;73(1):56-63,
65.

Rosenthal JR, Koh HK. Malignant melanoma and
pigmented lesions: a review. Compr Ther 1988
May;14(5):16-23.

Roush GC, Barnhill RL, Emstoff MS, Kirkwood JM.
Inter-clinician agreement on the recognition of
clinical pigmentary characteristics of patients with
cutaneous malignant melanoma. Studies of
melanocytic nevi, VI. Br J Cancer 1991 Aug;64(2):
373-6.

Saida T, Yoshida N, Ikegawa S, Ishihara K, Nakajima
T. Clinical guidelines for the early detection of
plantar malignant melanoma. J Am Acad Dermatol
1990 Jul;23(1):37-40.

Steiner A, Pehamberger H, Wolff K. In vivo
epiluminescence microscopy of pigmented skin
lesions. II. Diagnosis of small pigmented skin
lesions and early detection of malignant melanoma.
J Am Acad Dermatol 1987 Oct;17(4):584-91.

Van Viloten WA. Clinical diagnosis of cutaneous
melanomas. Dev Oncol 1984;25:72-80.

Pathology

Ackerman AB. Malignant melanoma in situ: the flat,
curable stage of malignant melanoma. Pathology
1985 Apr;17(2):298-300.

Bansal RK, Bhaduri AS, Pancholi YJ, Balar DB.
Cellular blue nevus with nevus cells in regional
lymph nodes: a lesion that mimics melanoma.
Indian J Cancer 1989 Sep;26(3):145-50.

Barnhill RL, Mihm MC Jr. Pigmented spindle cell
naevus and its variants: distinction from melanoma.
Br J Dermatol 1989 Dec;121(6):717-25.

Barr LH, Goldman LI, Solomon JA, Sanusi DI, Reed
RJ. Minimal deviation melanoma. Surg Gynecol
Obstet 1984 Dec;159(6):546-8.

Benda JA, Platz CE, Anderson B. Malignant
melanoma of the vulva: a clinical-pathologic review
of 16 cases. Int J Gynecol Pathol 1986;5(3):202-16.

Briggs JC. Melanoma precursor lesions and borderline
melanomas. Histopathology 1985 Dec;9(12):
1251-62.

Brodell RT, Santa Cruz DJ. Borderline and atypical
melanocytic lesions. Semin Diagn Pathol 1985 Feb;
2(1):63-86.

Clark WH Jr, Elder DE, Guerry D 4th, Epstein MN,
Greene MH, Van Horn M. A study of tumor
progression: the precursor lesions of superficial
spreading and nodular melanoma. Hum Pathol 1984
Dec;15(12):1147-65.

Colloby PS, West KP, Fletcher A. Observer variation
in the measurement of Breslow depth and Clark’s

level in thin cutaneous malignant melanoma.
J Pathol 1991 Mar;163(3):245-50.

Cook MG, Robertson I. Melanocytic dysplasia and
melanoma. Histopathology 1985 Jun;9(6):647-58.

Cooper PH, Wanebo HJ, Hagar RW. Regression in
thin malignant melanoma. Microscopic diagnosis
and prognostic importance. Arch Dermatol 1985
Sep;121(9):1127-31.

Curley RK, Cook MG, Fallowfield ME, Marsden RA.
Accuracy in clinically evaluating pigmented lesions
{see comments]. BMJ 1989 Jul 1;299(6690):16-8.
Comment in: BMJ 1989 Aug 5;299(6695):390.

Dubow BE, Ackerman AB. Ideas in pathology.
Malignant melanoma in situ: the evolution of a
concept. Mod Pathol 1990 Nov;3(6):734-44.
''Egbert B, Kempson R, Sagebiel R. Desmoplastic
malignant melanoma. A clinicohistopathologic study
of 25 cases. Cancer 1988 Nov 1;62(9):2033-41.

Elder DE, Guerry D 4th, Epstein MN, Zehngebot L,
Lusk E, Van Horn M, Clark WH Jr. Invasive
malignant melanomas lacking competence for
metastasis. Am J Dermatopathol 1984 Summer;
6 Suppl:55-61.

Flotte TJ. Malignant melanoma in situ. Hum Pathol
1990 Dec;21(12):1199-201.

Gamel JW, McLean IW. Computerized histopathologic
assessment of malignant potential. III. Refinements
of measurement and data analysis. Anal Quant
Cytol 1984 Mar;6(1):37-44.

Guerry D, Clark WH, Elder DE, Braitman LE, Trock
BJ, Schultz D, Synnestvedt M, Halpern AC. A
new prognostic model for clinical stage I melanoma
based on tumor progression and multivariate logistic
regression [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1989;8:A1102.

Guldhammer B, Norgaard T. The differential diagnosis
of intraepidermal malignant lesions using
immunohistochemistry. Am J Dermatopathol 1986
Aug;8(4):295-301.

Heenan PJ, Matz LR, Blackwell JB, Kelsall GR, Singh
A, ten Seldam RE, Holman CD. _Inter-observer
variation between pathologists in the classification
of cutaneous malignant melanoma in western
Australia. Histopathology 1984 Sep;8(5):717-29.

Imam A, Mitchell MS, Modlin RL, Taylor CR, Kempf
RA, Kan-Mitchell J. Human monoclonal antibodies
that distinguish cutaneous melanomas from benign
nevi in fixed sections. In: Reif AE, Mitchell MS,
editors. Immunity to cancer. New York: Academic
Press; 1985. p. 125-30.

Jackson R. Epidermotropic malignant melanoma: the
distinction between metastatic and new primary
lesions in the skin. Can J Surg 1984 Nov;27(6):
533-5.

Jimbow K, Horikoshi T, Takahashi H, Akutsu Y, Maeda
K. Fine structural and immunohistochemical
properties of dysplastic melanocytic nevi:
comparison with malignant melanoma. J Invest
Dermatol 1989 May;92(5 Suppl):304S-309S.

Jimbow K, Salopek TG, Dixon WT, Searles GE,
Yamada K. The epidermal melanin unit in the
pathophysiology of malignant melanoma. Am J
Dermatopathol 1991 Apr;13(2):179-88.

Kibbi AG, Mihm MC Jr. Malignant melanoma with
desmoplasia and neurotropism. J Dermatol Surg
Oncol 1987 Nov;13(11):1204-8.

Klein LJ, Barr RJ. Histologic atypia in clinically
benign nevi. A prospective study. J Am Acad
Dermatol 1990 Feb;22(2 Pt 1):275-82.

Kwittken J. Cutaneous melanocytic dysplasia and
malignant melanoma. A critical review. J Med
1991;22(1):1-16.

Langer K, Rappersberger K, Steiner A, Konrad K, Wolff
K. The ultrastructure of dysplastic naevi:
comparison with superficial spreading melanoma
and common naevocellular naevi. Arch Dermatol
Res 1990;282(6):353-62.

Larsen TE, Mogensen SB, Holme I. Clinical and
histological intercorrelations in pigmented naevi
indicating potential melanoma precursor lesions.
APMIS 1988 Feb;96(2):147-54.

LeBoit PE, Van Fletcher H. A comparative study of
Spitz nevus and nodular malignant melanoma using
image analysis cytometry. J Invest Dermatol 1987
Jun;88(6):753-7.

Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow
P, Riethm:uller G, Johnson JP. Discrimination
between benign and malignant cells of melanocytic
lineage by two novel antigens, a glycoprotein with a
molecular weight of 113,000 and a protein with a
molecular weight of 76,000. Cancer Res 1987
Feb 1;47(3):841-5.

Mackie RM, Campbell I, Turbitt ML. Use of NK1 C3
monoclonal antibody in the assessment of benign
and malignant melanocytic lesions. J Clin Pathol
1984 Apr;37(4):367-72.

Maeda K, Maeda K, Jimbow K. Specification and use
of a mouse monoclonal antibody raised against
melanosomes for the histopathologic diagnosis of
amelanotic malignant melanoma. Cancer 1988
Sep 1;62(5):926-34.

Maize JC, Ackerman AB. Pigmented lesions of the
skin. Philadelphia: Lea and Febiger; 1987. 328 p.

Malignant melanoma: biology, diagnosis, and therapy.
Cancer Treat Res 1988;43:1-202.

Marks R, Dorevitch AP, Mason G. Do all melanomas
come from "moles"? A study of the histological
association between melanocytic naevi and
melanoma. Australas J Dermatol 1990;31(2):77-80.

McGovern VJ. Melanoma: histological diagnosis and
prognosis. New York: Raven Press; 1983. 197 pp.

McGovern VJ, Cochran AJ, Van der Esch EP, Little JH,
MacLennan R. The classification of malignant
melanoma, its histological reporting and registration:
a revision of the 1972 Sydney classification.
Pathology 1986 Jan;18(1):12-21.
''4

McGovern VJ, Murad TM. Pathology of melanoma: an
overview. In: Balch CM, Milton GW, editors.
Cutaneous melanoma. Clinical management and
treatment results worldwide. Philadelphia: J.B.
Lippincott Company; 1985. p. 29-53.

Morishima T, Nagashima N, Hanawa S, Fukada E,
Kanematsu S, Shibata A. Quick diagnosis of
malignant melanoma with the touch-fluorescence
method during operation. Cancer 1986 May 15;
57(10):2037-41.

Morishima T, Tatsumi F, Fukada E, Watanabe M,
Nagashima N, Hanawa S. Studies on amelanotic
melanoma with the fluorescence method (Falck and
Hillarp) and biochemical analysis of 5-S-
cysteinyldopa in the tissues. Arch Dermatol Res
1983;275(5):329-33.

Muhlbauer JE, Margolis RJ, Mihm MC Jr, Reed RJ.
Minimal deviation melanoma: a histologic variant of
cutaneous malignant melanoma in its vertical growth
phase. J Invest Dermatol 1983 Jun;80 Supp!:
63s-65s.

Murphy GF, Mihm MC Jr. Histologic reporting of
malignant melanoma. Monogr Pathol 1988;(30):
79-93,

Nield DV, Saad MN, Khoo CT, Lott M, Ali MH.
Tumour thickness in malignant melanoma: the
limitations of frozen section. Br J Plast Surg 1988
Jul;41(4):403-7.

Penneys NS. Excision of melanoma after initial
biopsy. An immunohistochemical study. J Am
Acad Dermatol 1985 Dec;13(6):995-8.

Peters MS, Goellner JR. Spitz naevi and malignant
melanomas of childhood and adolescence.
Histopathology 1986 Dec;10(12):1289-302.

Phillips ME, Margolis RJ, Merot Y, Sober AJ, Reed RJ,
Muhlbauer JE, Mihm MC Jr. The spectrum of
minimal deviation melanoma: a clinicopathologic
study of 21 cases. Hum Pathol 1986 Aug;17(8):
796-806.

Rampen FH, Menzel S, Rumke P. Pathology delay and
misinterpretation in melanoma diagnosis [abstract].
Paper presented at: 13th International Pigment Cell
Conference; 1986 Oct 5-9; Tucson, AZ.

Reed RJ. The histological variance of malignant
melanoma: the interrelationship of histological
subtype, neoplastic progression, and biological
behaviour. Pathology 1985 Apr;17(2):301-12.

Reed RJ, Webb SV, Clark WH Jr. Minimal deviation
melanoma (halo nevus variant). Am J Surg Pathol
1990 Jan;14(1):53-68.

Rhodes AR, Melski JW, Sober AJ, Harrist TJ, Mihm
MC Jr, Fitzpatrick TB. Increased intraepidermal
melanocyte frequency and size in dysplastic
melanocytic nevi and cutaneous melanoma. A
comparative quantitative study of dysplastic
melanocytic nevi, superficial spreading melanoma,
nevocellular nevi, and solar lentigines. J Invest
Dermatol 1983 May;80(5):452-9.

Rogers GS, Advani H, Ackerman AB. A combined
variant of Spitz’s nevi. How to differentiate them
from malignant melanomas. Am J Dermatopathol
1985;7 Suppl:61-78.

Rosen L, Amazon K, Frank B. Bowen's disease,
Paget’s disease, and malignant melanoma in situ.
South Med J 1986 Apr;79(4):410-3.

Sagebiel RW. Diagnosis and management of
premalignant melanocytic proliferations. Pathology
1985 Apr;17(2):285-90.

Sagebiel RW. Diagnosis and management of
premalignant melanocytic proliferations. Pathology
1985 Apr;17(2):285-90.

Saida T, Yoshida N. Guidelines for histopathologic
diagnosis of plantar malignant melanoma. Two-
dimensional coordination of maximum diameters of
lesions and degrees of intraepidermal proliferation
of melanocytes. Dermatologica 1990;181(2):112-6.

Schmoeckel C. How consistent are dermatopathologists
in reading early malignant melanomas and lesions
"precursor" to them? An international survey. Am J
Dermatopathol 1984 Summer;6 Suppl:13-24.

Sexton M, Sexton CW. Recurrent pigmented
melanocytic nevus. A benign lesion, not to be
mistaken for malignant melanoma. Arch Pathol Lab
Med 1991 Feb;115(2):122-6.

Shafir R, Hiss J, Tsur H, Bubis JJ. Pitfalls in frozen
section diagnosis of malignant melanoma. Cancer
1983;51(6):1168-70.

Smithers BM, McLeod GR, Little JH. Desmoplastic,
neural transforming and neurotropic melanoma: a
review of 45 cases. Aust N Z J Surg 1990 Dec;
60(12):967-72.

Stolz W, Schmoeckel C, Welkovich B, Braun-Falco O.
Semiquantitative analysis of histologic criteria in
thin malignant melanomas [see comments]. J Am
Acad Dermatol 1989 Jun;20(6):1115-20. Comment
in: J Am Acad Dermatol 1990 Apr;22(4):698-9.

Thomson W, MacKie RM. Comparison of five
antimelanoma antibodies for identification of
melanocytic cells on tissue sections in routine
dermatopathology. J Am Acad Dermatol 1989 Dec;
21(6):1280-4.
''van der Esch EP. Histopathology of cutaneous
malignant melanoma. Dev Oncol 1984;25:97-111.

van Duinen SG, Ruiter DJ, Hageman P, Vennegoor C,
Dickersin GR, Scheffer E, R:umke P.
Immunohistochemical and histochemical tools in the
diagnosis of amelanotic melanoma. Cancer 1984
Apr 1;53(7):1566-73.

Wade TR, White CR Jr. The histology of malignant
melanoma. Med Clin North Am 1986 Jan;70(1):
57-70.

Walsh NM, Roberts JT, Orr W, Simon GT.
Desmoplastic malignant melanoma. A
clinicopathologic study of 14 cases.
Arch Pathol Lab Med 1988 Sep;112(9):
922-7.

Walts AE, Said JW, Shintaku IP. Cytodiagnosis of
malignant melanoma. Immunoperoxidase staining
with HMB-45 antibody as an aid to diagnosis.
Am J Clin Pathol 1988 Jul;90(1):77-80.

Xu X, Azumi N, Skelton H, Hearing VJ, Gersten DM.
Immunostaining of human malanomas by
monoclonal antibodies to B700 mouse melanoma
antigen [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1991;32:A1430.

Yamana K, Maeda K, Jimbow K. Application of
MoAb HMSA-2 for immunohistopathologic
diagnosis of amelanotic and/or regressed lesions of
human melanoma on routine paraffin sections
[abstract]. Paper presented at: 13th International
Pigment Cell Conference; 1986 Oct 5-9; Tucson,
AZ.

Zitelli JA, Moy RL, Abell E. The reliability of frozen
sections in the evaluation of surgical margins for
melanoma. J Am Acad Dermatol 1991 Jan;24(1):
102-6.

Dysplastic Nevus Syndrome and Dysplastic
Nevi

Ackerman AB. What naevus is dysplastic, a syndrome
and the commonest precursor of malignant
melanoma? A riddle and an answer [see comments].
Histopathology 1988 Sep;13(3):241-56. Comment
in: Histopathology 1989 Jul;15(1):103-8.

Ahmed I, Piepkorn MW, Rabkin MS, Meyer LJ,
Feldkamp M, Goldgar DE, Skolnick MH, Zone JJ.
Histopathologic characteristics of dysplastic nevi.
Limited association of conventional histologic
criteria with melanoma risk group. J Am Acad
Dermatol 1990 May;22(5 Pt 1):727-33.

Albert LS, Rhodes AR, Sober AJ. Dysplastic
melanocytic nevi and cutaneous melanoma: markers
of increased melanoma risk for affected persons and
blood relatives. J Am Acad Dermatol 1990 Jan;
22(1):69-75.

Augustsson A, Stierner U, Suurk:ula M, Rosdahl I.
Prevalence of common and dysplastic naevi in a
Swedish population. Br J Dermatol 1991 Feb;
124(2):152-6.

Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr,
Fraser MC, Stanger BZ, Green P, Donis-Keller H,
Housman DE, Greene MH. Mapping the gene for
hereditary cutaneous malignant melanoma-dysplastic
nevus to chromosome 1p [published erratum appears
in N Engl J Med 1991 Mar 28;324(13):925] [see
comments]. N Engl J Med 1989 May 25;320(21):
1367-72. Comments in: N Engl J Med 1990
Mar 22;322(12):853-4; N Engl J Med 1991 Mar 28;
324(13):925.

Barnhill RL, Hurwitz S, Duray PH, Arons MS. The
dysplastic nevus: recognition and management.
Plast Reconstr Surg 1988 Feb;81(2):280-9.

Barnhill RL, Kiryu H, Sober AJ, Mihm MC Jr.
Frequency of dysplastic nevi among
nevomelanocytic lesions submitted for
histopathologic examination. Time trends over a 37-
year period. Arch Dermatol 1990 Apr;126(4):463-5.

Barnhill RL, Roush GC. Correlation of clinical and
histopathologic features in clinically atypical
melanocytic nevi. Cancer 1991 Jun 15;67(12):
3157-64.

Barnhill RL, Roush GC. Histopathologic spectrum of
clinically atypical melanocytic nevi. II. Studies of
nonfamilial melanoma [published erratum appears in
Arch Dermatol 1990 Dec;126(12):1616]. Arch
Dermatol 1990 Oct;126(10):1315-8.
''6

Black WC. Residual dysplastic and other nevi in
superficial spreading melanoma. Clinical correlations
and association with sun damage. Cancer 1988
Jul 1;62(1):163-73.

Black WC, Hunt WC. Histologic correlations with the
clinical diagnosis of dysplastic nevus. Am J Surg
Pathol 1990 Jan;14(1):44-52.

Cannon-Albright LA, Goldgar DE, Wright EC, Turco A,
Jost M, Meyer LJ, Piepkorn M, Zone JJ, Skolnick
MH. _ Evidence against the reported linkage of the
cutaneous melanoma-dysplastic nevus syndrome
locus to chromosome Ip36. Am J Hum Genet 1990
May;46(5):912-8.

Caporaso N, Greene MH, Tsai S, Pickle LW, Mulvihill
JJ. Cytogenetics in hereditary malignant melanoma
and dysplastic nevus syndrome: is dysplastic nevus
syndrome a chromosome instability disorder?
Cancer Genet Cytogenet 1987 Feb;24(2):299-314.

Clemente C, Cochran AJ, Elder DE, Levene A, MacKie
RM, Mihm MC, Rilke F, Cascinelli N, Fitzpatrick
TB, Sober AJ. Histopathologic diagnosis of
dysplastic nevi: concordance among pathologists
convened by the World Health Organization
Melanoma Programme. Hum Pathol 1991 Apr;
22(4):313-9.

Cockerell CJ, Berson DS. A retrospective look at
dysplastic nevi. What were they in 1978 and how
have they fared since? Am J Dermatopathol 1985,
7 Suppl:93-7.

Cook MG, Fallowfield ME. Dysplastic naevi--an
alternative view. Histopathology 1990 Jan;
16(1):29-35.

Cooke KR, Spears GF, Elder DE, Greene MH.
Dysplastic naevi in a population-based survey.
Cancer 1989 Mar 15;63(6):1240-4.

Crijns MB, Vink J, Van Hees CL, Bergman W, Vermeer
BJ. Dysplastic nevi. Occurrence in first- and
second-degree relatives of patients with ‘sporadic’
dysplastic nevus syndrome. Arch Dermatol 1991
Sep;127(9):1346-51.

Crutcher WA, Cohen PJ. The dysplastic nevus
syndrome. In: Schwartz RA, editor. Skin cancer.
Recognition and management. New York: Springer;
1988. p.141-51.

Elder DE. Dysplastic nevi. Their significance and
management. Dermatol Clin 1988 Apr;6(2):257-69.

Elder DE. The dysplastic nevus. Pathology 1985 Apr;
17(2):291-7.

English DR, Menz J, Heenan PJ, Elder DE, Watt JD,
Armstrong BK. The dysplastic naevus syndrome in

patients with cutaneous malignant melanoma in
Western Australia. Med J Aust 1986 Sep 1;
145(5):194-8.

Greene MH. The dysplastic nevus syndrome:
precursors of heredity and nonfamilial cutaneous
melanoma. Import Adv Oncol 1986:173-91.

Greene MH, Clark WH Jr, Tucker MA, Kraemer KH,
Elder DE, Fraser MC. High risk of malignant
melanoma in melanoma-prone families with
dysplastic nevi. Ann Intern Med 1985 Apr;
102(4):458-65.

Greene MH, Goldin LR, Clark WH Jr, Lovrien E,
Kraemer KH, Tucker MA, Elder DE, Fraser MC,
Rowe S. Familial cutaneous malignant melanoma:
autosomal dominant trait possibly linked to the Rh
locus. Proc Natl Acad Sci U S A 1983 Oct;
80(19):6071-5.

Grob JJ, Andrac L, Romano MH, Davin D, Collet-
Villette AM, Munoz MH, Bonerandi JJ. Dysplastic
naevus in non-familial melanoma. A
clinicopathological study of 101 cases. Br J
Dermatol 1988 Jun;118(6):745-52.

Kraemer KH, Greene MH. Dysplastic nevus syndrome.
Familial and sporadic precursors of cutaneous
melanoma. Dermatol Clin 1985 Apr;3(2):225-37.

Lynch HT, Fusaro RM. Hereditary malignant
melanoma: a unifying etiologic hypothesis. Cancer
Genet Cytogenet 1986 Feb 15;20(3-4):301-4.

Lynch HT, Fusaro RM, Albano WA, Pester J,
Kimberling WJ, Lynch JF. Phenotypic variation in
the familial atypical multiple mole-melanoma
syndrome (FAMMM). J Med Genet 1983;20(1):
25-9.

Lynch HT, Fusaro RM, Kimberling WJ, Lynch JF,
Danes BS. Familial atypical multiple mole-
melanoma (FAMMM) syndrome: segregation
analysis. J Med Genet 1983 Oct;20(5):342-4.

MacKie RM. Critical remarks on the dysplastic naevus
syndrome. Dev Oncol 1984;25:249-52.

Nordlund JJ, Kirkwood J, Forget BM, Scheibner A,
Albert DM, Lerner E, Milton GW. Demographic
study of clinically atypical (dysplastic) nevi in
patients with melanoma and comparison subjects.
Cancer Res 1985 Apr;45(4):1855-61.

Piepkorn M, Meyer LJ, Goldgar D, Seuchter SA,
Cannon-Albright LA, Skolnick MH, Zone JJ. The
dysplastic melanocytic nevus: a prevalent lesion that
correlates poorly with clinical phenotype. J Am
Acad Dermatol 1989 Mar;20(3):407-15.
''Rhodes AR, Harrist TJ, Day CL, Mihm MC Jr, the Netherlands. Eur J Cancer Clin Oncol 1989
Fitzpatrick TB, Sober AJ. Dysplastic melanocytic Feb;25(2):337-41.
nevi in histologic association with 234 primary
cutaneous melanomas. J Am Acad Dermatol 1983
Oct;9(4):563-74.

Rhodes AR, Mihm MC Jr, Weinstock MA. Dysplastic
melanocytic nevi: a reproducible histologic
definition emphasizing cellular morphology
[published erratum appears in Mod Pathol 1989
Sep;2(5):426] [see comments]. Mod Pathol 1989
Jul;2(4):306-19. Comment in: Mod Pathol 1990
Jan;3(1):99.

Rigel DS, Rivers JK, Kopf AW, Friedman RJ, Vinokur
AF, Heilman ER, Levenstein M. Dysplastic nevi.
Markers for increased risk for melanoma. Cancer
1989 Jan 15;63(2):386-9.

Rivers JK, Cockerell CJ, McBride A, Kopf AW.
Quantification of histologic features of dysplastic
nevi. Am J Dermatopathol 1990 Feb;12(1):42-50.

Rivers JK, Kopf AW, Vinokur AF, Rigel DS, Friedman
RJ, Heilman ER, Levenstein M. Clinical
characteristics of malignant melanomas developing
in persons with dysplastic nevi. Cancer 1990
Mar 1;65(5):1232-6.

Roth ME, Grant-Kels JM, Ackerman AB, Elder DE,
Friedman RJ, Heilman ER, Maize JC, Sagebiel RW.
The histopathology of dysplastic nevi. Continued
controversy. Am J Dermatopathol 1991 Feb;13(1):
38-51.

Roush GC, Barnhill RL, Duray PH, Titus LJ, Emstoff
MS, Kirkwood JM. Diagnosis of the dysplastic
nevus in different populations. J Am Acad
Dermatol 1986 Mar;14(3):419-25.

Seywright MM, Doherty VR, MacKie RM. Proposed
alternative terminology and subclassification of so
called "dysplastic naevi." J Clin Pathol 1986 Feb;
39(2):189-94,

Steijlen PM, Bergman W, Hermans J, Scheffer E, Van
Vloten WA, Ruiter DJ. The efficacy of
histopathological criteria required for diagnosing
dysplastic naevi. Histopathology 1988 Mar;12(3):
289-300.

Tiersten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS,
Rigel DS, Friedman RJ, Levenstein MJ.
Prospective follow-up for malignant melanoma in
patients with atypical-mole (dysplastic-nevus)
syndrome. J Dermatol Surg Oncol 1991 Jan;
17(1):44-8.

Vasen HF, Bergman W, van Haeringen A, Scheffer E,
van Slooten EA. The familial dysplastic nevus
syndrome. Natural history and the impact of
screening on prognosis. A study of nine families in
''8

Evaluation of Patient and Family Following
Diagnosis

Anton-Guirgis H, Kurosaki T, Lynch HT, Ferrone S.
Biomarkers in multiple cases of malignant
melanoma and first-degree relatives. In: Anton-
Guirgis H, Lynch HT, editors. Biomarkers,
genetics, and cancer. New York: Van Nostrand
Reinhold Company; 1985. p. 168-83.

Ardizzoni A, Grimaldi A, Repetto L, Bruzzone M,
Sertoli MR, Rosso R. Stage I-II melanoma: the
value of metastatic work-up. Oncology 1987;
44(2):87-9.

Bukh A, Muller-Larsen A, Aguado MT, Muller-Larsen
F, Muller NP. Prognostic value of serial
determinations of circulating immune complex

levels in malignant melanoma. Cancer Immunol
Immunother 1988;26(3):280-4.

Gupta BK, Piedmonte MR, Karakousis CP. Attributes
and survival patterns of multiple primary cutaneous
malignant melanoma. Cancer 1991 Apr 1;67(7):
1984-9.

Gutman M, Cnaan A, Inbar M, Shafir R, Chaitchik S,
Rozin RR, Klausner JM. Are malignant melanoma
patients at higher risk for a second cancer? Cancer
1991 Aug 1;68(3):660-5.

Gutman M, Klausner JM, Inbar M, Rozin RR. Late
recurrence of stage I malignant melanoma. J Surg
Oncol 1989 Oct;42(2):96-8.

Iscoe N, Kersey P, Gapski J, Osoba D, From L, DeBoer
G, Quirt I. Predictive value of staging
investigations in patients with clinical stage I
malignant melanoma. Plast Reconstr Surg 1987
Aug;80(2):233-9.

Kelly JW, Blois MS, Sagebiel RW. Frequency and
duration of patient follow-up after treatment of a
primary malignant melanoma. J Am Acad Dermatol
1985 Nov;13(5 Pt 1):756-60.

Ketcham AS, Balch CM. Cutaneous melanoma:
classification and staging systems. In: Balch CM,
Milton GW, editors. Cutaneous melanoma. Clinical
management and treatment results worldwide.
Philadelphia: J.B. Lippincott Company; 1985.

p. 55-62.

Khansur T, Sanders J, Das SK. Evaluation of staging
workup in malignant melanoma. Arch Surg 1989
Jul; 124(7):847-9.

Koh HK, Sober AJ, Kopf A, Day CL, McKusick KA,
Lew RA, Fitzpatrick TB. Prognosis in Stage 1
malignant melanoma: seven-year follow-up study of

splenic radiocolloid uptake as predictor of death.
J Nucl Med 1984 Nov;25(11):1183-9.

Lederman JS, Sober AJ. Does biopsy type influence
survival in clinical stage I cutaneous melanoma?
J Am Acad Dermatol 1985 Dec;13(6):983-7.

McEwan L, Smith JG, Matthews JP. Late recurrence
of localized cutaneous melanoma: its influence on
follow-up policy. Plast Reconstr Surg 1990 Sep;
86(3):527-34.

McGuire DB. Preventive health practices and
educational needs in families with hereditary
melanoma. Cancer Nurs 1985;8(1):29-36.

McGuire DB. Preventive health practices and
educational needs in families with hereditary
melanoma. Cancer Nurs 1985;8(1):29-36.

Rigel DS, Friedman RJ. The management of patients
with dysplastic and congenital nevi. Dermatol Clin
1985 Apr;3(2):251-5.

Schultz S, Kane M, Roush R, Miller V, Berd D,
Goldman L, Mastrangelo M. Time to recurrence
varies inversely with thickness in clinical stage 1
cutaneous melanoma. Surg Gynecol Obstet 1990
Nov;171(5):393-7.

Titus-Emstoff L, Ernstoff MS, Kirkwood JM, Barnhill
RL, Fine J, Duray PH. Usefulness of frequent skin
examination for the early detection of second

primary cutaneous melanoma. Cancer Detect Prev
1989;13(S-6):317-21.

Tucker MA, Boice JD Jr, Hoffman DA. Second cancer
following cutaneous melanoma and cancers of the
brain, thyroid, connective tissue, bone, and eye in
Connecticut, 1935-82. Natl Cancer Inst Monogr
1985 Dec;68:161-89.

Tucker MA, Crutcher WA, Hartge P, Sagebiel RW.
Dysplastic nevi patients frequently have family
members with dysplastic nevi or cutaneous
melanoma [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1989;30:A1270.

Wagner RF Jr, Pellegrini JR, Delzell E. Decreased risk
of subsequent primary noncutaneous malignancies
among patients with primary cutaneous malignant
melanoma. J Dermatol Surg Oncol 1985 Nov;
11(11):1097-102.
''Epidemiology, Prevention, and Treatment

Ackerman AB, Scheiner AM. How wide and deep is
wide and deep enough? A critique of surgical
practice in excisions of primary cutaneous malignant
melanoma. Hum Pathol 1983 Sep;14(9):743-4.

Adams CM, Giltman LI. Elective lymph node
dissection in stage I melanoma--necessary or not?
Am Surg 1985 Sep;51(9):504-7.

Aitken DR, Clausen K, Klein JP, James AG. The
extent of primary melanoma excision. A re-
evaluation--how wide is wide? Ann Surg 1983
Nov;198(5):634-41.

Aitken DR, James AG, Carey LC. Local cutaneous
recurrence after conservative excision of malignant
melanoma. Arch Surg 1984 Jun;119(6):643-6.

Albino AP, Houghton AN. Cell surface antigens of
melanocytes and melanoma. Cancer Surv 1985;
4(1):185-211.

Ang KK, Byers RM, Peters LJ, Maor MH, Wendt CD,
Morrison WH, Hussey DH, Goepfert H. Regional
radiotherapy as adjuvant treatment for head and
neck malignant melanoma. Preliminary results.
Arch Otolaryngol Head Neck Surg 1990 Feb;
116(2):169-72.

Anton-Culver H, Culver BD, Kurosaki T. Malignant
melanoma subtypes: histology and anatomic sites
[abstract]. Paper presented at: International
Association of Cancer Registries Annual Meeting;
1990 Aug 13-15; Hamburg, Germany.

Ariyan S, Kirkwood JM. Malignant melanoma. In:
Ariyan S, editor. Cancer of the head and neck.
Washington: C.V. Mosby; 1987. p. 757-83.

Armstrong BK. Epidemiology of malignant melanoma:
intermittent or total accumulated exposure to the
sun? J Dermatol Surg Oncol 1988 Aug;14(8):
835-49.

Azizi E, Wax Y, Lusky A, Kushelevsky A, Schewach-
Millet M. The recovery from ultraviolet radiation-
induced erythema and melanoma risk factors: a
case-control study. J Am Acad Dermatol 1990 Jul;
23(1):30-6.

Baas PC, Hoekstra HJ, Schraffordt Koops H, Oosterhuis
JW, Oldhoff J. Isolated regional perfusion in the
treatment of subungual melanoma. Arch Surg 1989
Mar;124(3):373-6.

Balch CM. Clinical management of cutaneous
melanoma. In: McKenna RJ, Murphy GP, editors.
Fundamentals of surgical oncology. New York:
Macmillan Publishing Company; 1986. p. 420-39.

9

Balch CM. Excising melanomas: how wide is enough?
And how to reconstruct? J Surg Oncol 1990 Jul;
44(3):135-7.

Balch CM. The role of elective lymph node dissection
in melanoma: rationale, results, and controversies.
J Clin Oncol 1988 Jan;6(1):163-72.

Balch CM, Cascinelli N, Milton GW, Sim FH.
Elective lymph node dissection: pros and cons. In:
Balch CM, Milton GW, editors. Cutaneous
melanoma. Clinical management and treatment
results worldwide. Philadelphia: J.B. Lippincott
Company; 1985. p. 131-57.

Balch CM, Hersey P. Cutaneous melanoma: current
status of adjuvant therapy. In: Balch CM, Milton
GW, editors. Cutaneous melanoma. Clinical
management and treatment results worldwide.
Philadelphia: J.B. Lippincott Company; 1985.

p. 197-218.

Balch CM, Houghton A, Peters L. Cutaneous
melanoma. In: DeVita, VT Jr, et al., editors.
Cancer: principles and practice of oncology. 3rd ed.
Philadelphia: Lippincott; 1989. p. 1499-542.

Balch CM, Mettlin C. Melanoma in the United States:
a national survey of 4800 patients. In: Balch CM,
Milton GW, editors. Cutaneous melanoma. Clinical
management and treatment results worldwide.
Philadelphia: J.B. Lippincott Company; 1985.

p. 389-95.

Balch CM, Milton GW, editors. Cutaneous melanoma.
Clinical management and treatment results
worldwide. Philadelphia: J.B. Lippincott Company;
1985. 538 p.

Balch CM, Shaw HM, Soong SJ, Milton GW.
Changing trends in the clinical and pathologic
features of melanoma. In: Balch CM, Milton GW,
editors. Cutaneous melanoma. Clinical management
and treatment results worldwide. Philadelphia: J.B.
Lippincott Company; 1985. p. 313-9.

Balch CM, Soong SJ, Shaw HM, Milton GW. An
analysis of prognostic factors in 4000 patients with
cutaneous melanoma. In: Balch CM, Milton GW,
editors. Cutaneous melanoma. Clinical management
and treatment results worldwide. Philadelphia: J.B.
Lippincott Company; 1985. p. 321-52.

Balch CM, Urist MM, Maddox WA, Soong SJ.
Melanoma in the southern United States: experience
at the University of Alabama in Birmingham. In:
Balch CM, Milton GW, editors. Cutaneous
melanoma. Clinical management and treatment
results worldwide. Philadelphia: J.B. Lippincott
Company; 1985. p. 397-406.
''10

Bale SJ, Greene MH, Murray C, Goldin LR, Johnson
AH, Mann D. Hereditary malignant melanoma is
not linked to the HLA complex on chromosome 6.
Int J Cancer 1985 Oct 15;36(4):439-43.

Banzet P, Jacquillat C, Israel L, Puissant A, Bonvalet D,
Weil M, Khayat D. Prognostic value of clinical
and pathological parameters of stage I malignant
melanoma (MM) on a multivariate analysis: the
experience of the French Group of Research on MM
(FGRMM) on 475 cases followed from 15 to 113
months [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1986;27:186.

Banzet P, Jacquillat C, Khayat D, Pompidou A,
Soubrane C, Banzet M, Bazex PA, Lauret P, Verola
O, Civatte J, et al. Preliminary results of a
nonspecific immunotherapy using a new
isoprinosine schedule for adjuvant treatment of low-
risk (LR) malignant melanoma [abstract]. Proc
Annu Meet Am Soc Clin Oncol 1991;10:A1043.

Beenken S, Byers R, Smith JL, Goepfert H,
Shallenberger R. Desmoplastic melanoma.
Histologic correlation with behavior and treatment.
Arch Otolaryngol Head Neck Surg 1989 Mar;
115(3):374-9.

Beitner H, Norell SE, Ringborg U, Wennersten G,
Mattson B. Malignant melanoma: aetiological
importance of individual pigmentation and sun
exposure. Br J Dermatol 1990 Jan;122(1):43-51.

Beral V, Evans S, Shaw H, Milton G. Cutaneous
factors related to the risk of malignant melanoma.
Br J Dermatol 1983 Aug;109(2):165-72.

Berdeaux DH, Meyskens FL Jr, Parks B, Tong T,
Loescher L, Moon TE. Cutaneous malignant
melanoma. II. The natural history and prognostic
factors influencing the development of stage II
disease. Cancer 1989 Apr 1;63(7):1430-6.

Bergfelt L, Newell GR, Sider JG, Kripke ML.
Incidence and anatomic distribution of cutaneous
melanoma among United States Hispanics. J Surg
Oncol 1989 Apr;40(4):222-6.

Bilik R, Kahanovich S, Rubin M, Rothem A, Gelernter
I, Kaplan I. Morbidity and recurrence rates after
surgical treatment of malignant melanoma by scalpel
versus CO2 laser beam. Surg Gynecol Obstet 1987
Oct;165(4):333-8.

Binder M, Pehamberger H, Steiner A, Wolff K.
Elective regional lymph node dissection in
malignant melanoma. Eur J Cancer 1990;26(8):
871-3.

Blake PR. The treatment of malignant melanoma by
fast neutrons. Cancer Treat Res 1987;35:195-213.

Blessing K, McLaren KM, McLean A, Davidson P.
Thin malignant melanomas (less than 1.5 mm) with
metastasis: a histological study and survival
analysis. Histopathology 1990 Nov;17(5):389-95.

Blois MS, Sagebiel RW, Abarbanel RM, Caldwell TM,
Tuttle MS. Malignant melanoma of the skin. I.
The association of tumor depth and type, and patient
sex, age, and site with survival. Cancer 1983 Oct 1;
52(7):1330-41.

Boddie AW Jr, Balch CM. Three unresolved issues in
the surgical treatment of melanoma. Oncology
(Williston Park) 1988 Nov;2(11):39-44, 48-50.

Boddie AW Jr, McBride CM. Melanoma in childhood
and adolescence. In: Balch CM, Milton GW,
editors. Cutaneous melanoma. Clinical management
and treatment results worldwide. Philadelphia: J.B.
Lippincott Company; 1985. p. 63-70.

Bowsher WG, Taylor BA, Hughes LE. Morbidity,
mortality and local recurrence following regional
node dissection for melanoma. Br J Surg 1986
Nov;73(11):906-8.

Brandt SE, Welvaart K, Hermans J. Is long-term
follow-up justified after excision of a thin melanoma
(less than or equal to 1.5 mm)? A retrospective
analysis of 206 patients. J Surg Oncol 1990 Mar;
43(3):157-60.

Brannon BR, Wagstaff DA. Skin cancer/melanoma
public and professional education in Hawaii: an
integrated approach to technology transfer. Prog
Clin Biol Res 1983;120:497-508.

Briele HA, Beattie CW, Ronan SG, Chaudhuri PK, Das
Gupta TK. Late recurrence of cutaneous
melanoma. Arch Surg 1983 Jul;118(7):800-3.

Briele HA, Walker MJ, Das Gupta TK. Melanoma of
the head and neck. Clin Plast Surg 1985 Jul;
12(3):495-504.

Briggs JC, Ibrahim NB, Hastings AG, Griffiths RW.
Experience of thin cutaneous melanomas (less than
0.76 mm and less than 0.85 mm thick) in a large
plastic surgery unit: a 5 to 17 year follow-up. Br J
Plast Surg 1984 Oct;37(4):501-6.

Brocker EB, Suter L, Czarnetzki BM, Macher E. BCG
immunotherapy in stage I melanoma patients. Does
it influence prognosis determined by HLA-DR
expression in high-risk primary tumors? Cancer
Immunol Immunother 1986;23(2):155-7.

Brown J, Kopf AW, Rigel DS, Friedman RJ.
Malignant melanoma in World War II veterans. Int
J Dermatol 1984 Dec;23(10):661-3.
''Burton RC. Immunotherapy of thick (greater than
1.5mm) stage I malignant melanoma with low-dose
alkylating agents and BCG [abstract]. In: The
Clinical Oncological Society of Australia Inc.
Cancer in the 1990’s: is more aggressive treatment
better? 17th Annual Scientific Meeting; 1990 Nov
26-28; Melbourne, Australia. Melbourne (Australia):
The Society; 1990. p. 124.

Bystryn JC. Immunosurveillance and melanoma.
J Invest Dermatol 1989 May;92(5 Suppl):
318S-320S.

Caldwell CB, Spiro RH. The role of parotidectomy in
the treatment of cutaneous head and neck
melanoma. Am J Surg 1988 Oct;156(4):318-22.

Cascinelli N. Narrow excision, (1-cm margin) a safe
procedure for this cutaneous melanoma. Results of
an international randomized clinical trial [abstract].
Paper presented at: Society of Surgical Oncology
43rd Annual Cancer Symposium and Society of
Head and Neck Surgeons 36th Annual Meeting;
1990 May 19-22; Washington, DC.

Cascinelli N, Marchesini R. Increasing incidence of
cutaneous melanoma, ultraviolet radiation and the
clinician. Photochem Photobiol 1989 Oct;50(4):
497-505.

Cascinelli N, Nava M, Vaglini M, Marolda R, Santinami
M, Rovini D, Clemente C. Melanoma in Italy:
experience at the National Cancer Institute of Milan.
In: Balch CM, Milton GW, editors. Cutaneous
melanoma. Clinical management and treatment
results worldwide. Philadelphia: J.B. Lippincott
Company; 1985. p. 447-59.

Clark WH Jr. The prevention of malignant melanoma
and death due to malignant melanoma [abstract].
Proc Annu Meet Am Assoc Cancer Res 1988;29:
532-3.

Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE,
Trock BJ, Schultz D, Synnestvedt M, Halpern AC.
Model predicting survival in stage I melanoma
based on tumor progression [see comments]. J Natl
Cancer Inst 1989 Dec 20;81(24):1893-904.
Comment in: J Natl Cancer Inst 1990 Apr 4;82(7):
626-7.

Cohen HJ, Cox E, Manton K, Woodbury M. Malignant
melanoma in the elderly. J Clin Oncol 1987 Jan;
5(1):100-6.

Cohen MH, Cohen BJ, Shotkin JD, Morrison PT.
Surgical prophylaxis of malignant melanoma. Ann
Surg 1991 Apr;213(4):308-14.

Coit D, Sauven P, Brennan M. Prognosis of thick
cutaneous melanoma of the trunk and extremity.
Arch Surg 1990 Mar;125(3):322-6.

11

Coit DG, Brennan MF. Extent of lymph node
dissection in melanoma of the trunk or lower
extremity. Arch Surg 1989 Feb;124(2):162-6.

Cooke KR, McNoe BM. Targeting early detection of
malignant melanoma of the skin. N Z Med J 1990
Nov 28;103(902):551-3.

Cooke KR, Skegg DC, Fraser J. Socio-economic
status, indoor and outdoor work, and malignant
melanoma. Int J Cancer 1984 Jul 15;34(1):57-62.

Cosimi AB, Sober AJ, Mihm MC, Fitzpatrick TB.
Conservative surgical management of superficially
invasive cutaneous melanoma. Cancer 1984
Mar 15;53(6):1256-9.

Cox EB, Vollmer RT, Seigler HF. Melanoma in the
southeastern United States: experience at the Duke
Medical Center. In: Balch CM, Milton GW,
editors. Cutaneous melanoma. Clinical management
and treatment results worldwide. Philadelphia: J.B.
Lippincott Company; 1985. p. 407-18.

Creagan ET. Malignant melanoma. In: Brain MC,
Carbone PP, editors. Current therapy in
hematology-oncology-3. Toronto: Decker; 1988.
p. 305-9.

Cristofolini M, Franceschi S, Tasin L, Zumiani G,
Piscioli F, Talamini R, La Vecchia C. Risk factors
for cutaneous malignant melanoma in a northern
Italian population. Int J Cancer 1987 Feb 15;
39(2):150-4.

Crowley NJ, Seigler HF. The role of elective lymph
node dissection in the management of patients with
thick cutaneous melanoma. Cancer 1990 Dec 15;
66(12):2522-7.

Day CL Jr, Lew RA. Malignant melanoma prognostic
factors 7: elective lymph node dissection.
J Dermatol Surg Oncol 1985 Mar;11(3):233-9.

Day CL Jr, Lew RA. Malignant melanoma prognostic
factors 3: surgical margins. J Dermatol Surg Oncol
1983 Oct;9(10):797-801.

Devereux DF. Diagnosis and management of
dysplastic nevus syndrome and early melanoma.
Oncology (USA) 1989;4(1):73-81.

Doherty VR, MacKie RM. Experience of a public
education programme on early detection of
cutaneous malignant melanoma. BMJ 1988 Aug 6;
297(6645):388-91.

Doherty VR, MacKie RM. Reasons for poor prognosis
in British patients with cutaneous malignant
melanoma. Br Med J [Clin Res] 1986 Apr 12;
292(6526):987-9.
''12

Donald PJ. Head and neck cancer: melanoma. In:
Donald PJ, editor. Head and neck cancer.
Management of the difficult case. Philadelphia:
W.B. Saunders Company; 1984. p. 313-29.

Drzewiecki KT, Frydman H, Andersen K, Poulsen H,
Ladefoged C, Vibe P. Malignant melanoma.
Changing trerids in factors influencing metastasis-
free survival from 1964 to 1982. Cancer 1990
Jan 15;65(2):362-6.

Dubin N, Moseson M, Pasternack BS. Sun exposure
and malignant melanoma among susceptible
individuals. Environ Health Perspect 1989 May;
81:139-51.

Dubin N, Pasternack BS, Moseson M. Simultaneous
assessment of risk factors for malignant melanoma
and non-melanoma skin lesions, with emphasis on
sun exposure and related variables. Int J Epidemiol
1990 Dec;19(4):811-9.

Dunkley MP, Morris AM. Cutaneous malignant
melanoma: audit of the diagnostic process. Ann R
Coll Surg Engl 1991 Jul;73(4):248-52.

Eastwood J, Baker TG. Cutaneous malignant
melanoma in West Yorkshire: II. A prospective
study of recurrence and prediction of lymph nodal
metastasis. Br J Cancer 1984 Jul;50(1):35-43.

Edwards MJ, McBride CM, Soong SJ, Boddie AW,
Balch CM. Treatment of stage I melanoma of the
extremity: a matched comparison of surgical
excision alone and with isolated limb perfusion
[abstract]. Paper presented at: 42nd Annual Cancer
Symposium of the Society of Surgical Oncology and
35th Annual Meeting of the Society of Head and
Neck Surgeons; 1989 May 21-24; San Francisco.

Edwards MJ, Soong SJ, Boddie AW, Balch CM,
McBride CM. Isolated limb perfusion for localized
melanoma of the extremity. A matched comparison
of wide local excision with isolated limb perfusion
and wide local excision alone. Arch Surg 1990
Mar;125(3):317-21.

Elberg JJ, Poulsen H, Ladefoged C. The influence of
resection margin on prognosis in clinical stage I
malignant melanoma of the lower leg. Scand J Plast
Reconstr Surg Hand Surg 1989;23(1):59-63.

Elder DE. Human melanocytic neoplasms and their
etiologic relationship with sunlight. J Invest
Dermatol 1989 May;92(5 Suppl):297S-303S.

Elder DE, Guerry D, Heiberger RM, LaRossa D,
Goldman LI, Clark WH, Thompson CJ, Matozzo I,
Van Horn M. Optimal resection margin for
cutaneous malignant melanoma. Plast Reconstr
Surg 1983;71(1):66-72.

Elder DE, Guerry D 4th, VanHorn M, Hurwitz S,
Zehngebot L, Goldman LI, LaRossa D, Hamilton R,
Bondi EE, Clark WH Jr. The role of lymph node
dissection for clinical stage I malignant melanoma
of intermediate thickness (1.51-3.99 mm). Cancer
1985 Jul 15;56(2):413-8.

Eldh J, Suurkula M, Holmstr:om H. Prognosis for
localized cutaneous melanoma treated with wide
excision only, with special reference to development
of regional node metastases. Tumori 1987 Feb 28;
73(1):51-4.

Elsmann HJ, Emst K, Suter L. Radiotherapy of
primary human melanomas--experiences and
suggestions. Strahlenther Onkol 1991 Jul;
167(7):387-91.

Elwood JM. Epidemiology and control of melanoma in
white populations and in Japan. J Invest Dermatol
1989 May;92(5 Suppl):214S-221S.

Elwood JM, Gallagher RP, Davison J, Hill GB.
Sunburn, suntan and the risk of cutaneous malignant
melanoma--The Western Canada Melanoma Study.
Br J Cancer 1985 Apr;51(4):543-9.

Elwood JM, Whitehead SM, Davison J, Stewart M, Galt
M. Malignant melanoma in England: risks
associated with naevi, freckles, social class, hair
colour, and sunburn. Int J Epidemiol 1990 Dec;
19(4):801-10.

Elwood JM, Williamson C, Stapleton PJ. Malignant
melanoma in relation to moles, pigmentation, and
exposure to fluorescent and other lighting sources.
Br J Cancer 1986 Jan;53(1):65-74.

Emmett EA. Dermatological screening. J Occup Med
1986 Oct;28(10):1045-50.

English DR, Armstrong BK. Identifying people at high
risk of cutaneous malignant melanoma: results from
a case-control study in Western Australia. Br Med J
[Clin Res] 1988 May 7;296(6632):1285-8.

Evans J, McCann BG. A new protocol for the
treatment of stage I cutaneous malignant melanoma;
interim results of the first 806 patients treated. Br J
Plast Surg 1990 Jul;43(4):426-30.

Evans RD, Kopf AW, Lew RA, Rigel DS, Bart RS,
Friedman RJ, Rivers JK. Risk factors for the
development of malignant melanoma--I: Review of
case-control studies. J Dermatol Surg Oncol 1988
Apr; 14(4):393-408.

Field SI. Melanoma/skin cancer screening in Michigan.
J Am Acad Dermatol 1987 Mar;16(3 Pt 1):578-83.
''Fisher JC. Safe margins for melanoma excision. Ann
Plast Surg 1985 Feb;14(2):158-61.

Fisher SR. Cutaneous malignant melanoma of the head
and neck. Laryngoscope 1989 Aug;99(8 Pt 1):
822-36.

Fisher SR, Gillespie CA, Seigler HF, Crocker IR.
Current management of cutaneous melanomas of the
head and neck. Cancer Treat Res 1987;32:245-67.

Fletcher JR, White CR Jr, Fletcher WS. Improved
survival rates of patients with acral lentiginous
melanoma treated with hyperthermic isolation
perfusion, wide excision, and regional
lymphadenectomy. Am J Surg 1986 May;151(5):
593-8.

Fortner JG, Rosen PP, Maclean BJ. Selective use of
wide excision with elective lymph node dissection
for malignant melanoma. Pathol Annu 1985;20
Pt 1:239-46.

Friedman RJ, Rigel DS. The clinical features of
malignant melanoma. Dermatol Clin 1985 Apr;
3(2):271-83.

Friedman RJ, Rigel DS, Heilman ER. The relationship
between melanocytic nevi and malignant melanoma.
Dermatol Clin 1988 Apr;6(2):249-56.

Friedman RJ, Rigel DS, Kopf AW. Early detection of
malignant melanoma: the role of physician
examination and self-examination of the skin.

CA 1985 May-Jun;35(3):130-51.

Friedman RJ, Rigel DS, Kopf AW, Lieblich L, Lew R,
Harris MN, Roses DF, Gumport SL, Ragaz A,
Waldo E, Levine J, Levenstein M, Koenig R, Bart
RS, Trau H. Favorable prognosis for malignant
melanomas associated with acquired melanocytic
nevi. Arch Dermatol 1983 Jun;119(6):455-62.

Friedman RJ, Rigel DS, Silverman MK, Kopf AW,
Vossaert KA. Malignant melanoma in the 1990s:
the continued importance of early detection and the
role of physician examination and self-examination
of the skin. CA Cancer J Clin 1991 Jul-Aug;41(4):
201-26.

Gallagher RP, Elwood JM, Threlfall WJ, Band PR,
Spinelli JJ. Occupation and risk of cutaneous
melanoma. Am J Ind Med 1986;9(3):289-94,

Gallagher RP, Elwood JM, Yang CP. Is chronic
sunlight exposure important in accounting for

increases in melanoma incidence? Int J Cancer
1989 Nov 15;44(5):813-5.

Gari LM, Rivers JK, Kopf AW. Melanomas arising in
large congenital nevocytic nevi: a prospective study.
Pediatr Dermatol 1988 Aug;5(3):151-8.

13

Garland FC, White MR, Garland CF, Shaw E, Gorham
ED. Occupational sunlight exposure and melanoma
in the U.S. Navy. Arch Environ Health 1990 Sep-
Oct;45(5):261-7.

Ghussen F, Nagel K, Groth W, M:uller JM, St:utzer H.
A prospective randomized study of regional
extremity perfusion in patients with malignant
melanoma. Ann Surg 1984 Dec;200(6):764-8.

Girgis A, Campbell EM, Redman S, Sanson-Fisher RW.
Screening for melanoma: a community survey of
prevalence and predictors [see comments]. Med J
Aust 1991 Mar 4;154(5):338-43. Comment in: Med
J Aust 1991 May 20;154(10):707-8.

Goldman LI, Byrd R. Narrowing resection margins for
patients with low-risk melanoma. Am J Surg 1988
Feb;155(2):242-4.

Graham S, Marshall J, Haughey B, Stoll H, Zielezny M,
Brasure J, West D. An inquiry into the
epidemiology of melanoma. Am J Epidemiol 1985
Oct;122(4):606-19.

Green A, MacLennan R, Siskind V. Common acquired
naevi and the risk of malignant melanoma. Int J
Cancer 1985 Mar 15;35(3):297-300.

Green A, Siskind V. Geographical distribution of
cutaneous melanoma in Queensland. Med J Aust
1983 Apr 30;1(9):407-10.

Green A, Siskind V, Bain C, Alexander J. Sunburn
and malignant melanoma. Br J Cancer 1985
Mar;51(3):393-7.

Griffiths RW, Briggs JC. Biopsy procedures, primary
wide excisional surgery and long term prognosis in
primary clinical stage I invasive cutaneous
malignant melanoma. Ann R Coll Surg Engl 1985
Mar;67(2):75-8.

Griffiths RW, Briggs JC. Incidence of locally
metastatic (‘recurrent’) cutaneous malignant
melanoma following conventional wide margin
excisional surgery for invasive clinical stage I
tumours: importance of maximal primary tumour
thickness. Br J Surg 1986 May;73(5):349-53.

Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano
MH, Collet AM, Noe MC, Diconstanzo MP,
Bonerandi JJ. Count of benign melanocytic nevi as
a major indicator of risk for nonfamilial nodular and
superficial spreading melanoma. Cancer 1990 Jul
15;66(2):387-95.

Hacene K, Le Doussal V, Brunet M, Lemoine F, Guerin
P, Hebert H. Prognostic index for clinical Stage I
cutaneous malignant melanoma. Cancer Res 1983
Jun;43(6):2991-6.
''14

Halpern AC, Guerry D 4th, Elder DE, Clark WH Jr,
Synnestvedt M, Norman S, Ayerle R. Dysplastic
nevi as risk markers of sporadic (nonfamilial)
melanoma. A case-control study. Arch Dermatol
1991 Jul;127(7):995-9.

Hannaford PC, Villard-Mackintosh L, Vessey MP, Kay
CR. Oral contraceptives and malignant melanoma.
Br J Cancer 1991 Mar;63(3):430-3.

Harrist TJ, Day CL Jr. Malignant melanoma:
prognostic factors. Cancer Treat Res 1987;
35:119-30,

Heenan PJ, Weeramanthri T, Holman CD, Armstrong
BK. Surgical treatment and survival from
cutaneous malignant melanoma. Aust N Z J Surg
1985 Jun;55(3):229-34.

Helmrich SP, Rosenberg L, Kaufman DW, Miller DR,
Schottenfeld D, Stolley PD, Shapiro S. Lack of an
elevated risk of malignant melanoma in relation to
oral contraceptive use. J Natl Cancer Inst 1984
Mar;72(3):617-20.

Hennrikus D, Girgis A, Redman S, Sanson-Fisher RW.
A community study of delay in presenting with
signs of melanoma to medical practitioners. Arch
Dermatol 1991 Mar;127(3):356-61.

Hersey P, Sillar RW, Howe CG, Burton RC, Darbar SV,
Foster HM, Collins SM, Bradley DE, Owens D.
Factors related to the presentation of patients with
thick primary melanomas. Med J Aust 1991 May 6;
154(9):583-7.

Hill GJ, Hill HZ, Blumenreich M. Treatment of
melanoma. In: Schwartz RA, editor. Skin cancer.
Recognition and management. New York: Springer;
1988. p. 390-417.

Hiyama DT. Malignant melanoma: current
management. Ohio Med 1990 May;86(5):360-5.

Ho VC, Sober AJ. Therapy for cutaneous melanoma:
an update. J Am Acad Dermatol 1990 Feb;22(2 Pt
1):159-76.

Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of
melanocytic nevi as a major risk factor for
malignant melanoma. J Am Acad Dermatol 1987
Sep;17(3):459-68.

Holman CD, Armstrong BK. Pigmentary traits, ethnic
origin, benign nevi, and family history as risk
factors for cutaneous malignant melanoma. J Natl
Cancer Inst 1984 Feb;72(2):257-66.

Holman CD, Armstrong BK, Heenan PJ. Relationship
of cutaneous malignant melanoma to individual
sunlight-exposure habits. J Natl Cancer Inst 1986
Mar;76(3):403-14.

Hove LM, Akslen LA, Hartveit F. Malignant
melanoma of the skin. Changing clinical stage at
presentation, 1955-1979. Oncology 1987;44(3):
156-8.

Illig L. Epidemiologic aspects of malignant melanoma
(review). Anticancer Res 1987 Nov-Dec;7(6):
1309-13.

Illig L, Weidner F, Hundeiker M, Gartmann H, Biess B,
Leyh F, Paul E. Congenital nevi less than or equal
to 10 cm as precursors to melanoma. 52 cases, a
review, and a new conception. Arch Dermatol 1985
Oct;121(10):1274-81.

Ingvar C, Erichsen C, J:onsson PE. Morbidity
following prophylactic and therapeutic lymph node
dissection for melanoma--a comparison. Tumori
1984 Dec 31;70(6):529-33.

Iscoe N, From L, Gruss JG, McKenzie M, Jambrosic J,
Semple J, Myhr T, Hume S. The influence of
narrow surgical excision of clinical stage I
melanoma of the skin on local recurrence and
survival [abstract]. Proc Annu Meet Am Soc Clin
Oncol 1990;9:A1078.

Karakousis CP, Emrich LJ, Rao U. Prediction of
survival in primary melanomas according to
thickness [abstract]. Proc Annu Meet Am Assoc
Cancer Res 1988;29:A692.

Karakousis CP, Emrich LJ, Rao U. Tumor thickness
and prognosis in clinical stage I malignant
melanoma. Cancer 1989 Oct 1;64(7):1432-6.

Karakousis CP, Kachrimanidis S, Rao U, Emrich LJ.
Changes in survival with clinical stage I malignant
melanoma. J Surg Oncol 1987 Mar;34(3):155-9.

Karjalainen S, Hakulinen T. Survival and prognostic
factors of patients with skin melanoma. A
regression-model analysis based on nationwide
cancer registry data. Cancer 1988 Nov 15;
62(10):2274-80.

Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy
WH. Hereditary melanoma in Australia. Variable
association with dysplastic nevi and absence of
genetic linkage to chromosome 1p. Cancer Genet
Cytogenet 1991 Jan;51(1):45-55.

Kelly JW, Holly EA, Shpall SN, Ahn DK. The
distribution of melanocytic naevi in melanoma
patients and control subjects. Australas J Dermatol
1989;30(1):1-8.

Khan MS, Ross WM. Management of malignant
melanoma: a retrospective analysis of 182 patients.
Clin Radiol 1984 Mar;35(2):151-4.
''Khan MS, Ross WM. Prognostic factors in malignant
melanoma: a retrospective analysis of 182 patients.
Clin Radiol 1985 Nov;36(6):611-3.

Kirkpatrick CS, Lee JA, White E. Melanoma risk by
age and socio-economic status. Int J Cancer 1990
Jul 15;46(1):1-4.

Kissin MW, Simpson DA, Easton D, White H,
Westbury G. Prognostic factors related to survival
and groin recurrence following therapeutic lymph
node dissection for lower limb malignant melanoma.
Br J Surg 1987 Nov;74(11):1023-6.

Kleeberg UR. Etiology and risk factors of melanoma.
Ann Ital Chir 1989 Jul-Aug;60(4):231-6.

Kleeberg UR. Etiology of melanoma. Onkologie 1988
Dec;11(6):254-9.

Koh HK, Geller AC, Miller DR, Caruso A, Gage I, Lew
RA. Who is being screened for melanoma/skin
cancer? Characteristics of persons screened in
Massachusetts. J Am Acad Dermatol 1991 Feb;24
(2 Pt 1):271-7.

Koh HK, Lew RA, Prout MN. Screening for
melanoma/skin cancer: theoretic and practical
considerations. J Am Acad Dermatol 1989 Feb;20(2
Pt 1):159-72.

Koh HK, Michalik E, Sober AJ, Lew RA, Day CL,
Clark W, Mihm MC, Kopf AW, Blois MS,
Fitzpatrick TB. Lentigo maligna melanoma has no
better prognosis than other types of melanoma.

J Clin Oncol 1984 Sep;2(9):994-1001.

Koh HK, Sober AJ, Day CL Jr, Lew RA, Kopf AW,
Lamar W, Ben Cosimi A, Wood WC, Mihm MC Jr,
Malt RA, et al. Prognosis of clinical stage I
melanoma patients with positive elective regional
node dissection. J Clin Oncol 1986 Aug;4(8):
1238-44.

Kopf AW. Prevention and early detection of skin
cancer/melanoma. Cancer 1988 Oct 15;62(8 Suppl):
1791-5.

Kopf AW. Prevention of malignant melanoma.
Dermatol Clin 1985 Apr;3(2):351-2, 354, 358-60.

Kopf AW, Gross DF, Rogers GS, Rigel DS, Hellman
LJ, Levenstein M, Welkovich B, Friedman RJ,
Roses DF, Bart RS, et al. Prognostic index for
malignant melanoma. Cancer 1987 Mar 15;59(6):
1236-41.

Kopf AW, Kripke ML, Stern RS. Sun and malignant
melanoma. J Am Acad Dermatol 1984 Oct;11(4 Pt
1):674-84.

15

Landthaler M, Braun-Falco O, Leitl A, Konz B, H:olzel
D. Excisional biopsy as the first therapeutic
procedure versus primary wide excision of
malignant melanoma. Cancer 1989 Oct 15;64(8):
1612-6.

Lederman JS, Sober AJ. Does wide excision as the
initial diagnostic procedure improve prognosis in
patients with cutaneous melanoma? J Dermatol
Surg Oncol 1986 Jul;12(7):697-9.

Lee JA. The causation of melanoma. In: Blach CM,
Milton GW, editors. Cutaneous melanoma. Clinical
management and treatment results worldwide.
Philadelphia: J.B. Lippincott Company; 1985.

p. 303-11.

Lee JA. The relationship between malignant melanoma
of skin and exposure to sunlight. Photochem
Photobiol 1989 Oct;50(4):493-6.

Lee JA. The rising incidence of cutaneous malignant
melanoma. Am J Dermatopathol 1985;7 Suppl:35-9.

Legha SS. Current therapy for malignant melanoma.
Semin Oncol 1989 Feb;16(1 Suppl 1):34-44.

Lejeune FJ. Epidemiology and etiology of malignant
melanoma. Biomed Pharmacother 1986;40(3):91-9.

Lejeune FJ, Li:enard D, el Douaihy M, Seyedi JV,
Ewalenko P. Results of 206 isolated limb
perfusions for malignant melanoma. Eur J Surg
Oncol 1989 Dec;15(6):510-9.

Lew RA, Koh HK, Sober AJ. Epidemiology of
cutaneous melanoma. Dermatol Clin 1985 Apr;
3(2):257-69.

Lew RA, Sober AJ, Cook N, Marvell R, Fitzpatrick TB.
Sun exposure habits in patients with cutaneous
melanoma: a case control study. J Dermatol Surg
Oncol 1983 Dec;9(12):981-6.

Lindegard B. Mortality and fatality of cutaneous
malignant melanoma in Sweden, 1982-1986.
Biomed Pharmacother 1990;44(10):495-501.

Loggie BW, Eddy JA. Solar considerations in the
development of cutaneous melanoma. Semin Oncol
1988 Dec;15(6):494-9,

MacKie RM. Risk factors, diagnosis, and detection of
melanoma. Curr Opin Oncol 1991 Apr;3(2):360-3.

MacKie RM. The epidemiology of melanoma. Dev
Oncol 1984;25:1-8.

MacKie RM, Freudenberger T, Aitchison TC. Personal
risk-factor chart for cutaneous melanoma [see
comments]. Lancet 1989 Aug 26;2(8661):487-90.
Comment in: Lancet 1989 Sep 30;2(8666):799.
''16

Masri GD, Clark WH Jr, Guerry D 4th, Halpern A,
Thompson CJ, Elder DE. Screening and
surveillance of patients at high risk for malignant
melanoma result in detection of earlier disease.

J Am Acad Dermatol 1990 Jun;22(6 Pt 1):1042-8.

Mastrangelo MJ, Baker AR, Katz HR. Cutaneous
melanoma. In: DeVita VT Jr, Hellman S,
Rosenberg SA, editors. Cancer - principles and
practice of oncology. 2nd ed. Philadelphia:
Lippincott; 1985. p. 1371-422.

McGovern VJ, Shaw HM, Milton GW. Prognosis in
patients with thin malignant melanoma: influence of
regression. Histopathology 1983 Sep;7(5):673-80.

Meyskens FL Jr, Edwards L, Levine NS. Role of
topical tretinoin in melanoma and dysplastic nevi.
J Am Acad Dermatol 1986 Oct;15(4 Pt 2):822-5.

Morris BT, Sober AJ. Cutaneous malignant melanoma
in the older patient. Dermatol Clin 1986 Jul;
4(3):473-80.

Moy RL, Zitelli JA. Success using Mohs micrographic
surgery for the treatment of melanoma [abstract].
Paper presented at: 2nd International Conference on
Head and Neck Cancer; 1988 Jul 31-Aug 5; Boston,
MA.

Muel B, Cesarini JP, Elwood JM. Malignant
melanoma and fluorescent lighting. Int Congr Ser
1987;744:89-96.

Naruns PL, Nizze JA, Cochran AJ, Lee MB, Morton
DL. Recurrence potential of thin primary
melanomas. Cancer 1986 Feb 1;57(3):545-8.

Newell GR, Sider JG, Bergfelt L, Kripke ML.
Incidence of cutaneous melanoma in the United
States by histology with special reference to the
face. Cancer Res 1988 Sep 1;48(17):5036-41.

Nichols S. Beware of the mid-day sun. Public
awareness of the risk of malignant melanoma. Nurs
Times 1988;84(23):38-9.

Osterlind A. Etiology and epidemiology of melanoma
and skin neoplasms. Curr Opin Oncol 1991 Apr;
3(2):355-9.

Osterlind A. Malignant melanoma in Denmark.
Occurrence and risk factors. Acta Oncol 1990;
29(7):833-54.

Osterlind A, Tucker MA, Stone BJ, Jensen OM. The
Danish case-control study of cutaneous malignant
melanoma. IV. No association with nutritional
factors, alcohol, smoking or hair dyes. Int J Cancer
1988 Dec 15;42(6):825-8.

Osterlind A, Tucker MA, Stone BJ, Jensen OM. The
Danish case-control study of cutaneous malignant
melanoma. III. Hormonal and reproductive factors in
women. Int J Cancer 1988 Dec 15;42(6):821~4.

Osterlind A, Tucker MA, Stone BJ, Jensen OM. The
Danish case-control study of cutaneous malignant
melanoma. II. Importance of UV-light exposure. Int
J Cancer 1988 Sep 15;42(3):319-24.

Polednak AP. Seasonal patterns in the diagnosis of
malignant melanoma of skin and eye in upstate New
York. Cancer 1984 Dec 1;54(11):2587-94.

Polk HC Jr. Individual treatment for malignant
melanoma. J Surg Oncol 1989 Jan;40(1):46-8.

Pritchard DJ, Sim FH. Surgical management of
malignant melanoma of the trunk and extremities.
Mayo Clin Proc 1989 Jul;64(7):846-51.

Rampen FH, Kint A, Hunter JA, Hulsebosch HJ.
Primary management of melanoma. Br J Dermatol
1984 Oct;111(4):431-6.

Rampen FH, van der Meeren HL, Boezeman JB.
Frequency of moles as a key to melanoma
incidence? J Am Acad Dermatol 1986 Dec;
15(6):1200-3.

Rhodes AR. Melanocytic precursors of cutaneous
melanoma. Estimated risks and guidelines for
management. Med Clin North Am 1986 Jan;70(1):
3-37.

Rhodes AR, Weinstock MA, Fitzpatrick TB, Mihm MC
Jr, Sober AJ. Risk factors for cutaneous
melanoma. A practical method of recognizing
predisposed individuals. JAMA 1987 Dec 4;
258(21):3146-54.

Rigel DS, Rogers GS, Friedman RJ. Prognosis of
malignant melanoma. Dermatol Clin 1985 Apr;
3(2):309-14.

Robinson JK. Familial and sporadic dysplastic nevi:
enhanced early detection [abstract]. Paper
presented at: Illinois Cancer Council Conference on
Melanoma; 1989 Nov 9; Chicago.

Robinson JF, Robinson WA. Malignant melanoma
(MM), a disease of lifestyle in the eighties
{abstract]. Proc Annu Meet Am Soc Clin Oncol
1987;6:A834.

Rogers GS. Narrow versus wide margins in malignant
melanoma [see comments]. J Dermatol Surg Oncol
1989 Jan;15(1):33-4. Comment in: J Dermatol Surg
Oncol 1989 Aug;15(8):881-2.

Rogers GS, Kopf AW, Rigel DS, Friedman RJ, Levine
JL, Levenstein M, Bart RS, Mintzis MM. Effect of
''anatomical location on prognosis in patients with
clinical stage I melanoma. Arch Dermatol 1983
Aug;119(8):644-9.

Rogers GS, Kopf AW, Rigel DS, Levenstein ML,
Friedman RJ, Harris MN, Golomb FM, Hennessey
P, Gumport SL, Roses DF, et al. Influence of
anatomic location on prognosis of malignant
melanoma: attempt to verify the BANS model.
J Am Acad Dermatol 1986 Aug;15(2 Pt 1):231-7.

Ronan SG, Eng AM, Briele HA, Shioura NN, Das
Gupta TK. Thin malignant melanomas with
regression and metastases. Arch Dermatol 1987
Oct;123(10):1326-30.

Roses DF, Harris MN. Malignant melanoma. In:
Nealon TF Jr, editor. Management of the patient
with cancer. 3rd ed. Philadelphia: WB Saunders
Company; 1986. p. 40-91.

Roses DF, Harris MN, Gumport SL. Surgery for
primary cutaneous malignant melanoma. Dermatol
Clin 1985 Apr;3(2):315-26.

Roses DF, Harris MN, Rigel D, Carrey Z, Friedman R,
Kopf AW. Local and in-transit metastases
following definitive excision for primary cutaneous
malignant melanoma. Ann Surg 1983 Jul;198(1):
65-9.

Roses DF, Provet JA, Harris MN, Gumport SL, Dubin
N. Prognosis of patients with pathologic stage II
cutaneous malignant melanoma. Ann Surg 1985
Jan;201(1):103-7.

Ross MI, Balch CM. The current management of
cutaneous melanoma. Adv Surg 1991;24:139-200.

Roush GC. Abnormal nevi, excess total nevi, and
melanoma: an epidemiologic perspective. Cancer
Treat Res 1988;43:85-100.

Roush GC, Nordlund JJ, Forget B, Gruber SB,
Kirkwood JM. Independence of dysplastic nevi
from total nevi in determining risk for nonfamilial
melanoma. Prev Med 1988 May;17(3):273-9.

Roush GC, Schymura MJ, Holford TR. Risk for
cutaneous melanoma in recent Connecticut birth
cohorts. Am J Public Health 1985 Jun;75(6):
679-82.

Salman SM, Rogers GS. Prognostic factors in thin
cutaneous malignant melanoma [see comments].
J Dermatol Surg Oncol 1990 May;16(5):413-8.
Comment in: J Dermatol Surg Oncol 1990 Sep;
16(9):877.

Schmoeckel C, Bockelbrink A, Bockelbrink H, Koutsis
J, Braun-Falco O. Low- and high-risk malignant
melanoma--I. Evaluation of clinical and histological

17

prognosticators in 585 cases. Eur J Cancer Clin
Oncol 1983 Feb;19(2):227-35.

Schmoeckel C, Bockelbrink A, Bockelbrink H, Kistler
H, Braun-Falco O. Low- and high-risk malignant
melanoma--III. Prognostic significance of the
resection margin. Eur J Cancer Clin Oncol 1983
Feb;19(2):245-9.

Schneebaum S, Briele HA, Walker MJ, Greager J,
Wood DK, Ronan SG, Patel MK, Das Gupta TK.
Cutaneous thick melanoma. Prognosis and treatment.
Arch Surg 1987 Jun;122(6):707-11.

Schreiber MM, Moon TE, Bozzo PD. Chronic solar
ultraviolet damage associated with malignant
melanoma of the skin. J Am Acad Dermatol 1984
May;10(5 Pt 1):755-9.

Schultz S, Kane M, Roush R, Miller V, Berd D,
Goldman L, Mastrangelo M. Inverse relationship
of tumor thickness and time to recurrence in patients
with clinical stage I cutaneous melanoma [abstract].
Proc Annu Meet Am Soc Clin Oncol 1989;8:A1111.

Scotto J, Fears TR. The association of solar ultraviolet
and skin melanoma incidence among caucasians in
the United States. Cancer Invest 1987;5(4):275-83.

Shaw HM, Beattie CW, McCarthy WH, Milton GW.
Late relapse from cutaneous stage I malignant
melanoma. Arch Surg 1985 Oct;120(10):1155-9.

Shaw HM, McCarthy WH, McCarthy SW, Milton GW.
Thin malignant melanomas and recurrence potential.
Arch Surg 1987 Oct;122(10):1147-50.

Shaw HM, McCarthy SW, McCarthy WH, Thompson
JF, Milton GW. Thin regressing malignant
melanoma: significance of concurrent regional
lymph node metastases. Histopathology 1989
Sep;15(3):257-65.

Shaw JH. Malignant melanoma in Auckland, New
Zealand. Surg Gynecol Obstet 1988 May;166(5):
425-30.

Shelley W, Kersey P, Quirt I, Pater J. Survey of
surgical management of malignant melanoma in
Canada: optimal margins of excision and lymph-
node dissection. Can J Surg 1984 Mar;27(2):190-2.

Silberman AW. Malignant melanoma. Practical
considerations concerning prophylactic regional
lymph node dissection. Ann Surg 1987 Aug;206(2):
206-9.

Sim FH, Taylor WF, Pritchard DJ, Soule EH.
Lymphadenectomy in the management of stage I
malignant melanoma: a prospective randomized
study. Mayo Clin Proc 1986 Sep;61(9):697-705.
''18

Slingluff CL Jr, Vollmer R, Seigler HF. Acral
melanoma: a review of 185 patients with
identification of prognostic variables. J Surg Oncol
1990 Oct;45(2):91-8.

Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF.
Lethal "thin" malignant melanoma. Identifying
patients at risk. Ann Surg 1988 Aug;208(2):150-61.

Sober AJ. Prognostic factors for cutaneous melanoma.
Dev Oncol 1984;25:126-42.

Sober AJ. Solar exposure in the etiology of cutaneous
melanoma. Photodermatol 1987 Feb;4(1):23-31.

Sober AJ, Day CL Jr, Fitzpatrick TB, Lew RA, Kopf
AW, Mihm MC Jr. Early death from clinical stage
I melanoma. J Invest Dermatol 1983 Jun;80 Suppl:
50s-52s.

Sober AJ, Day CL Jr, Fitzpatrick TB, Lew RA, Kopf
AW, Mihm MC Jr. Factors associated with death
from melanoma from 2 to 5 years following
diagnosis in clinical stage I patients. J Invest
Dermatol 1983 Jun;80 Suppl:53s-55s.

Sober AJ, Day CL Jr, Koh HK, Lew RA, Mihm MC Jr,
Kopf AW, Fitzpatrick TB. Melanoma in the
northeastern United States: experience of the
Melanoma Clinical Cooperative Group. In: Balch
CM, Milton GW, editors. Cutaneous melanoma.
Clinical management and treatment results
worldwide. Philadelphia: J.B. Lippincott Company;
1985. p. 437-46.

Sondergaard K, Hou-Jensen K. Partial regression in
thin primary cutaneous malignant melanomas
clinical stage I. A study of 486 cases. Virchows
Arch [A] 1985;408(2-3):241-7.

Sondergaard K, Schou G. Biopsy and optimal size of
margins of resection of primary cutaneous malignant
melanomas. Am J Dermatopathol 1985;7 Suppl:
127-9.

Sondergaard K, Schou G. Prognostic factors in primary
cutaneous malignant melanoma. Am J
Dermatopathol 1985;7 Suppl:1-4.

Sondergaard K, Schou G. Survival with primary
cutaneous malignant melanoma, evaluated from
2012 cases. A multivariate regression analysis.
Virchows Arch [A] 1985;406(2):179-95.

Soong SJ. A computerized mathematical model and
scoring system for predicting outcome in melanoma
patients. In: Balch CM, Milton GW, editors.
Cutaneous melanoma. Clinical management and
treatment results worldwide. Philadelphia: J.B.
Lippincott Company; 1985. p. 353-67.

Sorahan T, Grimley RP. The aetiological significance
of sunlight and fluorescent lighting in malignant
melanoma: a case-control study. Br J Cancer 1985
Nov;52(5):765-9.

Steiner A, Pehamberger H, Wolff K. In vivo
epiluminescence microscopy of pigmented skin
lesions. II. Diagnosis of small pigmented skin
lesions and early detection of malignant melanoma.
J Am Acad Dermatol 1987 Oct;17(4):584-91.

Sunba MS, Rahi AH, Morgan G, Donovan H.
Prognostic parameters in malignant melanoma of the
iris. In: Lommatzsch PK, Blodi FC, editors.
Intraocular tumors. New York: Springer-Verlag;
1983. p. 120-8.

Swerdlow AJ, English J, MacKie RM, O’Doherty CJ,
Hunter JA, Clark J, Hole DJ. Benign melanocytic
naevi as a risk factor for malignant melanoma. Br
Med J [Clin Res] 1986 Jun 14;292(6535):1555-9.

Swerdlow AJ, English JS, MacKie RM, O’Doherty CJ,
Hunter JA, Clark J, Hole DJ. Fluorescent lights,
ultraviolet lamps, and risk of cutaneous melanoma
[published erratum appears in BMJ 1988 Nov 5;
297(6657):1172]. BMJ 1988 Sep 10;297(6649):
647-50.

Swerdlow AJ, Green A. Melanocytic naevi and
melanoma: an epidemiological perspective. Br J
Dermatol 1987 Aug;117(2):137-46.

Tan GJ, Baak JP. Evaluation of prognostic
characteristics of stage I cutaneous malignant
melanoma. Anal Quant Cytol 1984 Sep;6(3):
147-54.

Taylor BA, Hughes LE. A policy of selective excision
for primary cutaneous malignant melanoma. Eur J
Surg Oncol 1985 Mar;11(1):7-13.

Taylor BA, Hughes LE, Williams GT. Improving
prognosis for malignant melanoma in Britain. Br J
Surg 1984 Dec;71(12):950-3.

Temoshok L, DiClemente RJ, Sweet DM, Blois MS,
Sagebiel RW. Factors related to patient delay in
seeking medical attention for cutaneous malignant
melanoma. Cancer 1984 Dec 15;54(12):3048-53.

Thorn M, Adami HO, Ringborg U, Bergstrom R,
Krusemo UB. Long-term survival in malignant
melanoma with special reference to age and sex as
prognostic factors. J Natl Cancer Inst 1987 Nov;
79(5):969-74.

Titus-Emnstoff L, Emstoff MS, Duray PH, Bamhill RL,
Holubkov R, Kirkwood JM. A relation between
childhood sun exposure and dysplastic nevus
syndrome among patients with nonfamilial
melanoma. Epidemiology 1991 May;2(3):210-4.
''Titus-Ernstoff L, Ernstoff M, Kirkwood J, Roush G,
Barnhill R, Fine J, Duray P. Dysplastic nevi, acute
sun exposure and risk for multiple primary
melanoma [abstract]. Proc Annu Meet Am Soc
Clin Oncol 1987;6:A895.

Tonak J, Hermanek P, Weidner F, Guggenmoos-
Holzmann I, Altendorf A. Melanoma in Germany:
experience at the University of Erlangen-Nurnberg.
In: Balch CM, Milton GW, editors. Cutaneous
melanoma. Clinical management and treatment
results worldwide. Philadelphia: J.B. Lippincott
Company; 1985. p. 483-94.

Tucker MA. Host and environmental factors in the
etiology of melanoma [abstract]. Proc Annu Meet
Am Assoc Cancer Res 1989;30:679-81.

Urist MM, Balch CM, Soong SJ, Milton GW, Shaw
HM, McGovern VJ, Murad TM, McCarthy WH,
Maddox WA. Head and neck melanoma in 534
clinical Stage I patients. A prognostic factors
analysis and results of surgical treatment. Ann Surg
1984 Dec;200(6):769-75.

Urist MM, Balch CM, Soong S, Shaw HM, Milton GW,
Maddox WA. The influence of surgical margins
and prognostic factors predicting the risk of local
recurrence in 3445 patients with primary cutaneous
melanoma. Cancer 1985 Mar 15;55(6):1398-402.

Urist MM, Maddox WA, Kennedy JE, Balch CM.
Patient risk factors and surgical morbidity after
regional lymphadenectomy in 204 melanoma
patients. Cancer 1983 Jun 1;51(11):2152-6.

Vagero D, Swerdlow AJ, Beral V. Occupation and
malignant melanoma: a study based on cancer
registration data in England and Wales and in
Sweden. Br J Ind Med 1990 May;47(5):317-24.

van der Esch EP, Muir CS, Nectoux J, Macfarlane G,
Maisonneuve P, Bharucha H, Briggs J, Cooke RA,
Dempster AG, Essex WB, et al. Temporal change
in diagnostic criteria as a cause of the increase of
malignant melanoma over time is unlikely. Int J
Cancer 1991 Feb 20;47(4):483-9.

van Egmond DB, Welvaart K, Hermans J, Ruiter DJ.
The effects of negative regional lymph-node
dissection on survival and disease-free interval of
patients with stage-I malignant melanoma [see
comments]. Neth J Surg 1990 Apr;42(2):43-6.
Comment in: Neth J Surg 1990 Dec;42(6):161-2.

Veronesi U, Bufalino R, Cascinelli N, Morabito A.
Long term results of randomized trial comparing
immediate versus delayed node dissection in stage I
melanoma of the limbs. Dev Oncol 1984;25:
165-80.

19

Veronesi U, Cascinelli N. Narrow excision (1-cm
margin). A safe procedure for thin cutaneous
melanoma. Arch Surg 1991 Apr;126(4):438-41.

Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera
D, Barchuk A, Bufalino R, Craig P, De Marsillac J,
Durand JC, et al. Thin stage I primary cutaneous
malignant melanoma. Comparison of excision with
margins of 1 or 3 cm [published erratum appears in
N Engl J Med 1991 Jul 25;325(4):292]. N Engl J
Med 1988 May 5;318(18):1159-62.

Veronesi U, et al, editors. Cutaneous melanoma: status
of knowledge and future perspective. New York:
Academic; 1987. 693 p.

Vreeburg GC, Schouwenburg PF, Hilgers FJ, de Kraker
NW, Hart AA. Cutaneous melanoma of the head
and neck. Eur J Surg Oncol 1988 Apr;14(2):
165-70.

Wagner DE, Cullen RA. Primary melanoma: pitfalls in
diagnostic biopsy techniques and interpretations.
Am J Surg 1984 Jul;148(1):99-102.

Walter SD, Marrett LD, Hertzman C. Reliability of
interviewer and subject assessments of nevus counts
in a study of melanoma. J Clin Epidemiol 1991;
44(7):633-40.

Wanebo HJ, Cooper PH, Hagar RW. Thin (less than or
equal to 1 mm) melanomas of the extremities are
biologically favorable lesions not influenced by
regression. Ann Surg 1985 Apr;201(4):499-504.

Wanebo HJ, Litle VR, Muchmore JH. Regional
perfusion for extremity lesions. In: Lokich JJ,
editor. Cancer chemotherapy by infusion. 2nd ed.
Chicago: Precept Press; 1990. p. 599-618.

Weinstock MA, Colditz GA, Willett WC, Stampfer MJ,
Bronstein BR, Mihm MC Jr, Speizer FE.
Melanoma and the sun: the effect of swimsuits and
a "healthy" tan on the risk of nonfamilial malignant
melanoma in women. Am J Epidemiol 1991 Sep 1;
134(5):462-70.

Weinstock MA, Colditz GA, Willett WC, Stampfer MJ,
Bronstein BR, Mihm MC Jr, Speizer FE. Moles
and site-specific risk of nonfamilial cutaneous
malignant melanoma in women. J Natl Cancer Inst
1989 Jun 21;81(12):948-52.

Weinstock MA, Colditz GA, Willett WC, Stampfer MJ,
Bronstein BR, Mihm MC Jr, Speizer FE.
Nonfamilial cutaneous melanoma incidence in
women associated with sun exposure before 20
years of age [see comments]. Pediatrics 1989
Aug;84(2):199-204. Comment in: Pediatrics 1990
Apr;85(4):626-7.
''20

Weinstock MA, Colditz GA, Willett WC, Stampfer MJ,
Rosner B, Speizer FE. Recall (report) bias and
reliability in the retrospective assessment of
melanoma risk. Am J Epidemiol 1991 Feb 1;
133(3):240-5.

Weinstock MA, Morris BT, Lederman JS, Bleicher P,
Fitzpatrick TB, Sober AJ. Effect of BANS location
on the prognosis of clinical stage I melanoma: new
data and meta-analysis. Br J Dermatol 1988 Nov;
119(5):559-65.

Weinstock MA, Sober AJ. The risk of progression of
lentigo maligna to lentigo maligna melanoma. Br J
Dermatol 1987 Mar;116(3):303-10.

Weinstock MA, Stryker WS, Stampfer MJ, Lew RA,
Willett WC, Sober AJ. Sunlight and dysplastic
nevus risk. Results of a clinic-based case-control
study. Cancer 1991 Mar 15;67(6):1701-6.

Welvaart K, Hermans J, Zwaveling A, Ruiter DJ.
Prognoses and surgical treatment of patients with
stage I melanomas of the skin: a retrospective
analysis of 211 patients. J Surg Oncol 1986 Feb;
31(2):79-86.

Whitehead SM, Wroughton MA, Elwood JM, Davison J,
Stewart M. Effects of a health education campaign
for the earlier diagnosis of melanoma. Br J Cancer
1989 Sep;60(3):421-5.

Williams HC, Smith D, du Vivier A. Melanoma.
Differences observed by general surgeons and
dermatologists. Int J Dermatol 1991 Apr;
30(4):257-61.

Wilson KS, Carmichael VE. Cutaneous malignant
melanoma: British Columbia Cancer Agency
experience from 1972-1981 [abstract]. Proc Annu
Meet Am Soc Clin Oncol 1991;10:A1047.

Wong JH, Sterns EE, Kopald KH, Nizze JA, Morton
DL. Prognostic significance of pregnancy in stage
I melanoma. Arch Surg 1989 Oct;124(10):1227-30;
discussion 1230-1.

Wong JH, Wanek L, Chang LJ, Goradia T, Morton DL.
The importance of anatomic site in prognosis in
patients with cutaneous melanoma. Arch Surg 1991
Apr; 126(4):486-9.

Woods JE. Management of malignant melanoma of the
head and neck. Mayo Clin Proc 1989 Jul;64(7):
861-3.

Woods JE, Taylor WF, Pritchard DJ, Sim FH, Ivins JC,
Bergstralh EJ. Is the BANS concept for malignant
melanoma valid? Am J Surg 1985 Oct;150(4):
452-5.

Wright WE, Peters JM, Mack TM. Organic chemicals
and malignant melanoma. Am J Ind Med 1983;
4(4):577-81.

Wyshak G, Frisch RE, Albright NL, Albright TE, Schiff
I. Reproductive factors and melanoma of the skin
among women. Int J Dermatol 1989 Oct;28(8):
527-30.

Zeitels J, LaRossa D, Hamilton R, Synnestvedt M,
Schultz D. A comparison of local recurrence and
resection margins for stage I primary cutaneous
malignant melanomas. Plast Reconstr Surg 1988
May;81(5):688-93.

Zitelli JA, Mohs FE, Larson P, Snow S. Mohs

micrographic surgery for melanoma. Dermatol Clin
1989 Oct;7(4):833-43.
''National Library of Medicine
Reference Bibliography Series

 

wea
ye

NATIONAL LIBRARY of MEDICINE

AIDS

BIBLIOGRAPHY

©

 

 

 

(-) ADS Bibliography *
$59 per year (12 Monthly issues)
Individual issues $5 per copy
List ID: AID91

Previously published quarterly.
Each issue consists of about 700-
900 recent references to journal
articles, books, and audiovisuals on
AIDS.

 

CURRENT
BIBLIOGRAPHIES
IN MEDICINE

 

Care and Use
of Laboratory
Animals

 

 

 

 

 

 

 

 

 

 

Medicine *
$52 per year (Approx. 20 Titles/yr.)
Individual issues $3 per copy

List ID: CBM91

A continuation of the Library's
Literature Search Series, which
ended in 1987. Topics will continue
to be chosen for their current
popular interest in distinct subject
areas of biomedicine (excluding
AIDS).

*Subscribers receive all issues for a given calendar year without regard to the date of order.

Superintendent of Documents Subscriptions Order Form

a = s3
Gow Pcs core GOOD Charge your order. eo i=
a a ¥ Its easy! GS aus

L] YES, please send me the subscription(s) indicated above. To fax your orders and inquiries— (202) 275-0019
The total cost of my order is $________. Prices include regular domestic postage and handling and are subject to change.

International customers please add 25%.

 

(Company or personal name) (Please type or print)

 

(Additional address/attention line)

 

(Street address)

 

(City, State, ZIP Code)
( )

(Daytime phone including area code)

Please Choose Method of Payment:
J Check payable to the Superintendent of Documents

LJ GPO Deposit Account LITT TIT] -T]

[ ] VISA or MasterCard Account

LITTLTIT TTT TTT TTT ttt oy

Thank you for your order!

 

(Credit card expiration date)

 

(Signature) 2/91

Mail To: Superintendent of Documents, Government Printing Office, Washington, DC 20402-9371
''zp
'' 

GRATEFUL MED© Software

For
Macintosh & IBM

 

Please send me SS Please send me
copies of GRATEFUL vit ua copies of GRATEFUL
MED for the pote ine MED for IBM and

compatibles.
Order No. PB86-
158482/GBB at $29.95

Macintosh.
Order No. PB89-
196083/GBB at $29.95

  

 

each. each.
Total Mac versions + Total IBM versions +
Handling $3.00 + Billing Fee* = Total

 

* Add $7.50 Billing Fee if using a Purchase Order.
Please attach this form to any purchase order you use.

P.O. #:

 

 

 

 

Send to:

U.S. Department of Commerce
National Technica] Information Service
5285 Port Royal Rd.

Springfield, VA 22161

Enclosed is check / money order payable to NTIS for
$F

Charge to (check one):

American Express [[] VISA [] MasterCard [_]

Card Number Exp.

Signature (required to validate order): Telephone: (703) 487-4650

For ordering by FAX: (703) 321-8547
(only for orders using credit card or purchase order)

 

Please complete the following.
Last Name: First Initial:

Title:

 

Company / Organization:

 

Address:

 

City / State / Zip:

 

Phone Number: ¢ )

 

In addition to your order you will receive free yearly upgrades of the software and information
on obtaining a user code required to access the National Library of Medicine's datafiles.

yr U. S. Government Printing Office: 1992 - 308-671 (50681)
''''PUBLIC HEAIT

OCT 261993

U.C. BERKELEY LIBRARIES

cpo4u1b53373

ypc
1 BE

wun

IIA
A

RY
'' 
''